Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Barclays analyst Eliana Merle upgraded Sagimet Biosciences Inc. (NASDAQ:SGMT) from Equal-Weight to Overweight and raised the price target from $8 to $18. Sagimet Biosciences closed at $10.71 on Tuesday. See how other analysts view this stock. B of A Securities analyst Craig Siegenthaler upgraded Figure Technology Solutions, Inc. (NASDAQ:FIGR) from Underperform to Neutral and boosted the price target from $31 to $49. Figure Technology shares closed at $38.26 on Tuesday. See how other analysts view this stock. UBS analyst Doug Schenkel upgraded Illumina, Inc. (NASDAQ:ILMN) from Neutral to Buy and raised the price target from $135 to $260. Illumina closed at $211.06 on Tuesday. See how other analysts view this stock. Wells Fargo analyst Timna Tanners upgraded Martin Marietta Materials, Inc. (NYSE:MLM) from Equal-Weight to Overweight and boosted the price target from $581 to $609. Martin Marietta Materials shares closed at $511.98 on Tuesday. See how other analysts view this stock. UBS analyst Doug Schenkel upgraded Waters Corporation (NYSE:WAT) from Neutral to Buy and raised the price target from $375 to $490. Waters closed at $402.91 on Tuesday. See how other analysts view this stock. Considering buying ILMN stock? Here’s what analysts think:
Photo via Shutterstock
Trending
Market News and Data brought to you by Benzinga APIs
Genomics is a comprehensive study of genomes (an organism’s complete set of deoxyribonucleic acid or DNA). Recent scientific advances in this area have heightened interest from pharmaceutical and biotechnology companies seeking deeper insight into disease biology and more effective therapeutic strategies.
A key point to note is the difference between genetics and genomics. While genetics focuses on individual genes, genomics primarily aims to characterize all the genes of an organism. Genomics involves understanding how they interact with one another and with environmental factors to influence biological processes.
Insights from genomic research are increasingly being used to evaluate how patients respond to specific drugs. These findings are also driving the development of precise, more targeted treatments, contributing to the advancement of personalized medicine. As demand for innovative therapies continues to grow, genomics is poised to play an increasingly central role in the future of healthcare, despite the complexity inherent in genome-scale research.
The expanding genomics landscape has also supported the growth of synthetic biology, which applies engineering principles to biology. This emerging field involves redesigning organisms for diverse applications, including drug discovery, disease detection, enzyme engineering, gene editing and foundational research.
The rapid progress in the novel space of genomics has been fueled by steep declines in the cost, time, and effort needed to sequence an individual’s genome. A major player in this field is Illumina (ILMN - Free Report) , a global leader in sequencing and array-based solutions for genetic and genomic analysis.
Diagnostic companies are using genomic sequencing data to identify genetic variations and connect them to known diseases. In contrast, other companies apply sequencing technologies to develop solutions across healthcare and other industries.
Another major advancement in the field is the emergence of genome-editing technologies, most notably CRISPR/Cas9. Companies specializing in gene editing, such as CRISPR Therapeutics AG (CRSP - Free Report) and Beam Therapeutics, Inc. (BEAM - Free Report) , are exploring these tools to potentially treat or even cure diseases caused by genetic mutations. As the name implies, these technologies enable precise modifications to an organism’s DNA, allowing scientists to correct harmful defects at their source.
According to Fortune Business Insights, the global genomics market was valued at $34.23 billion in 2025 and is expected to expand from $38.24 billion in 2026 to $99.26 billion by 2034, reflecting a compound annual growth rate (CAGR) of 12.66% over the period.
Per a Grandview Research article, the global synthetic biology market size was valued at $18.9 billion in 2025 and is projected to reach $69.2 billion by 2033, at a CAGR of 17.7% from 2026 to 2033.
If you're looking to capitalize on this trend, our Genomics and Synthetic Biology screen makes it easy to identify high-potential stocks at any given time. At present, stocks such as GENEDX HOLDINGS (WGS - Free Report) , NeoGenomics (NEO - Free Report) and Intellia Therapeutics (NTLA - Free Report) hold potential.
Explore 40 cutting-edge investment themes with Zacks Thematic Investing Screens and uncover your next big opportunity.
3 Genomics Stocks to ConsiderGeneDx Holdings is a leading player in rare disease diagnostics, focused on advancing genomic insights to improve patient outcomes. The company leverages deep clinical expertise, proprietary technology and its expansive GeneDx Infinity dataset — one of the largest rare disease genomic repositories globally — to support accurate and timely diagnoses.
Its core testing offerings, ExomeDx and GenomeDx, are highly regarded among clinicians and have received FDA Breakthrough Device Designation, underscoring their clinical utility and innovation. Beyond diagnostics, GeneDx is also positioning its dataset as a valuable asset for biopharma, enabling AI-driven discovery and development.
With more than 25 years of experience, over 4,800 genetic diseases diagnosed and a robust publication record, GeneDx is building a scalable genomics platform that could play a central role in the evolution of precision medicine.
WGS currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
NeoGenomics, Inc. is a leading provider of oncology diagnostic solutions that support precision medicine. The company operates a network of cancer-focused testing laboratories across the United States and the United Kingdom. It offers one of the most comprehensive oncology-focused testing menus spanning the cancer care continuum, serving oncologists, pathologists, hospital systems, academic medical centers and pharmaceutical companies. Its innovative diagnostic and predictive testing solutions provide timely, actionable insights that help guide personalized treatment and care decisions.
As of June 30, 2026, the company operated College of American Pathologists (“CAP”) accredited and Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) certified laboratories in Fort Myers, FL; Aliso Viejo and Carlsbad, CA; Research Triangle Park, NC; Ramsey, NJ; and Houston, TX; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NEO also has several small, non-processing laboratory locations across the United States to provide analysis services.
Shares of the company have surged 47.7% in the year so far. NEO currently carries a Zacks Rank #2 (Buy).
Intellia Therapeutics leverages its proprietary technologies and expertise, including CRISPR-based gene-editing technologies, oligonucleotides and lipid nanoparticles (LNPs), to develop novel, first-in-class therapeutic candidates. Its leading programs include lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) for the treatment of hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z, formerly NTLA-2001) for transthyretin (ATTR) amyloidosis.
These lead candidates represent the company’s most advanced programs and are the first in vivo genome-editing candidates to progress into phase III clinical development.
In April 2026, Intellia reported positive top-line results from the global phase III HAELO clinical trial evaluating lonvo-z in HAE.
Intellia expects the FDA to accept its biologics license application (BLA) seeking approval for lonvo-z in the second half of 2026. If approved, Intellia plans to launch lonvo-z commercially in the first half of 2027.
The company currently carries a Zacks Rank #3 (Hold).
Illumina (ILMN - Free Report) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.
The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.
Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.
As such, the Zacks rating upgrade for Illumina is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.
Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.
Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Illumina imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher.
Harnessing the Power of Earnings Estimate RevisionsAs empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .
Earnings Estimate Revisions for IlluminaFor the fiscal year ending December 2026, this genetic testing tools company is expected to earn $5.36 per share, which is unchanged compared with the year-ago reported number.
Analysts have been steadily raising their estimates for Illumina. Over the past three months, the Zacks Consensus Estimate for the company has increased 3%.
Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
You can learn more about the Zacks Rank here >>>
The upgrade of Illumina to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
Bloom Energy, Illumina and Everpure will join the S&P 500 index, S&P Dow Jones Indices announced late Friday. The three stocks rose in after-hours trading.
Bloom Energy (BE), Illumina (ILMN) and Everpure (P) will be added to the benchmark index before the open on Monday, Sept. 21, as part of a quarterly rebalancing of S&P indexes. They'll replace Molson Coors (TAP), Trade Desk (TTD) and Builders FirstSource (BLDR).
↑
X
Are High-Octane Stocks Back In Favor? Sandisk, Robinhood, Dell In Focus
Alissa Coram and Mike Webster walk through Friday’s market action and discuss key stocks to watch in Stock Market Today.
0 seconds of 1 hour, 20 minutes, 58 secondsVolume 0%
Press shift question mark to access a list of keyboard shortcuts
Ed Zitron: Big Tech Is 'Handing Money To Itself' To Inflate The AI Bubble
19:22
00:00
1:20:58
1:20:58
NOW PLAYING
Are High-Octane Stocks Back In Favor? Sandisk, Robinhood, Dell In Focus
Bloom Energy stock jumped 6% in Friday evening trading, set to gap above a short-term high of 253.31 . The fuel-cell maker, an AI power play, spiked 7.35% on Friday and 20% for the week to 252.87, surging above the 50-day moving average. Bloom Energy stock is building the right side of a new base with a 351.28 entry.
Illumina and Everpure rose about 2% in extended action.
Molson Coors, Trade Desk and Builders FirstSource were little changed.
Please follow Ed Carson on Threads at @edcarson1971 and X/Twitter at @IBD_ECarson for stock market updates and more.
YOU MIGHT ALSO LIKE:
Why This IBD Tool Simplifies The Search For Top Stocks
, /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P 100, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 21, 2026, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space.
Following is a summary of the changes that will take place prior to the open of trading on the effective date:
Effective Date
Index Name
Action
Company Name
Ticker
GICS Sector
Sept 21, 2026
S&P 100
Addition
Dell Technologies
DELL
Information Technology
Sept 21, 2026
S&P 100
Deletion
Honeywell Aerospace
HONA
Industrials
Sept 21, 2026
S&P 100
Addition
Palo Alto Networks
PANW
Information Technology
Sept 21, 2026
S&P 100
Deletion
NIKE
NKE
Consumer Discretionary
Sept 21, 2026
S&P 100
Addition
Arista Networks
ANET
Information Technology
Sept 21, 2026
S&P 100
Deletion
Simon Property Group
SPG
Real Estate
Sept 21, 2026
S&P 100
Addition
Sandisk
SNDK
Information Technology
Sept 21, 2026
S&P 100
Deletion
Colgate-Palmolive
CL
Consumer Staples
Sept 21, 2026
S&P 500
Addition
Bloom Energy
BE
Industrials
Sept 21, 2026
S&P 500
Deletion
Molson Coors Beverage
TAP
Consumer Staples
Sept 21, 2026
S&P 500
Addition
Everpure
P
Information Technology
Sept 21, 2026
S&P 500
Deletion
The Trade Desk
TTD
Communication Services
Sept 21, 2026
S&P 500
Addition
Illumina
ILMN
Health Care
Sept 21, 2026
S&P 500
Deletion
Builders FirstSource
BLDR
Industrials
Sept 21, 2026
S&P MidCap 400
Addition
HubSpot
HUBS
Information Technology
Sept 21, 2026
S&P MidCap 400
Deletion
Boston Beer
SAM
Consumer Staples
Sept 21, 2026
S&P MidCap 400
Addition
AGNC Investment
AGNC
Financials
Sept 21, 2026
S&P MidCap 400
Deletion
Capri Holdings
CPRI
Consumer Discretionary
Sept 21, 2026
S&P MidCap 400
Addition
Corcept Therapeutics
CORT
Health Care
Sept 21, 2026
S&P MidCap 400
Deletion
Everpure
P
Information Technology
Sept 21, 2026
S&P MidCap 400
Addition
Brinker Intl
EAT
Consumer Discretionary
Sept 21, 2026
S&P MidCap 400
Deletion
Illumina
ILMN
Health Care
Sept 21, 2026
S&P SmallCap 600
Addition
Herc Holdings
HRI
Industrials
Sept 21, 2026
S&P SmallCap 600
Deletion
N-able
NABL
Information Technology
Sept 21, 2026
S&P SmallCap 600
Addition
Delek US Holdings
DK
Energy
Sept 21, 2026
S&P SmallCap 600
Deletion
Shenandoah Telecommunications
SHEN
Communication Services
Sept 21, 2026
S&P SmallCap 600
Addition
AXT
AXTI
Information Technology
Sept 21, 2026
S&P SmallCap 600
Deletion
Matthews Intl
MATW
Consumer Discretionary
Sept 21, 2026
S&P SmallCap 600
Addition
Arcutis Biotherapeutics
ARQT
Health Care
Sept 21, 2026
S&P SmallCap 600
Deletion
Verra Mobility
VRRM
Industrials
Sept 21, 2026
S&P SmallCap 600
Addition
AtriCure
ATRC
Health Care
Sept 21, 2026
S&P SmallCap 600
Deletion
Franklin BSP Realty Trust
FBRT
Financials
Sept 21, 2026
S&P SmallCap 600
Addition
Capri Holdings
CPRI
Consumer Discretionary
Sept 21, 2026
S&P SmallCap 600
Deletion
NexPoint Residential Trust
NXRT
Real Estate
Sept 21, 2026
S&P SmallCap 600
Addition
Boston Beer
SAM
Consumer Staples
Sept 21, 2026
S&P SmallCap 600
Deletion
Amerisafe
AMSF
Financials
Sept 21, 2026
S&P SmallCap 600
Addition
Molson Coors Beverage
TAP
Consumer Staples
Sept 21, 2026
S&P SmallCap 600
Deletion
Cogent Communications Holdings
CCOI
Communication Services
Sept 21, 2026
S&P SmallCap 600
Addition
The Trade Desk
TTD
Communication Services
Sept 21, 2026
S&P SmallCap 600
Deletion
Corcept Therapeutics
CORT
Health Care
Sept 21, 2026
S&P SmallCap 600
Addition
Builders FirstSource
BLDR
Industrials
Sept 21, 2026
S&P SmallCap 600
Deletion
Brinker Intl
EAT
Consumer Discretionary
ABOUT S&P DOW JONES INDICES
S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.
S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spglobal.com/spdji/en/.
Key Takeaways Illumina raised 2026 revenue and EPS guidance as second-quarter revenues climbed 9.5% year over year. Oncology led clinical growth, while StrataMap Spatial and SomaLogic offerings broadened customer use cases. ILMN faces margin pressure from tariffs, freight and memory costs despite maintaining manageable leverage. Illumina Inc. (ILMN - Free Report) is well positioned for growth in the coming quarters, driven by strategic execution focused on growing its core sequencing business, expanding multiomics and developing services, data and software capabilities. Ongoing momentum in oncology is boosting clinical growth. Additionally, a strong solvency looks encouraging. However, input-cost volatility may constrain incremental margin expansion over the next several quarters.
Over the past year, this Zacks Rank #2 (Buy) stock has surged 129.6%, well ahead of the industry’s 24.6% growth and the S&P 500 composite’s rise of 20.1.%.
The renowned biotechnology company has a market capitalization of $27.82 billion. ILMN’s earnings yield of 2.4% is well ahead of the industry’s -14.9% yield. The company beat on earnings in each of the trailing four quarters, delivering an average surprise of 9.7%.
Let’s delve deeper.
Tailwinds Supporting ILMN StockSharpened Focus on Core Genomics: Following the June 2024 GRAIL spin-off, Illumina remains centered on its core sequencing franchise while extending into multiomics, data and software. The second-quarter 2026 results offered further evidence that the strategy is beginning to gain traction. Revenues rose 9.5% year over year to $1.16 billion, supported by continued demand across the business.
Management raised full-year 2026 revenue guidance to $4.60-$4.64 billion and adjusted earnings per share (EPS) guidance to $5.30-$5.40 while maintaining adjusted operating margin projection of 23.4-23.6%. The company continues to target high-single-digit revenue growth in 2027, supported by its core sequencing business, multiomics and data offerings. Together, these developments keep Illumina on track with its longer-term growth and profitability framework and support continued progress toward its stated targets.
Oncology Portfolio and Workflow Expansion Support Adoption: Illumina is broadening the workflows that can run within its sequencing ecosystem as clinical customers adopt larger, more data-intensive assays. In the second quarter of 2026, oncology continued to lead clinical growth, with therapy selection remaining the largest contributor and molecular residual disease (MRD) beginning to gain momentum.
The company also launched a whole-genome MRD research workflow for NovaSeq systems in early access, designed to shorten assay-development timelines and lower development costs. Beyond sequencing, the company launched StrataMap Spatial and continued to expand SomaScan and SomaSeq after the SomaLogic acquisition.
Image Source: Zacks Investment Research
BioInsight has begun generating revenues through the Billion Cell Atlas, which has delivered more than 300 million cells and added three partners after quarter-end, bringing the total to six biopharma partners. These offerings broaden customer use cases and support Illumina’s longer-term multiomics and data strategy.
Favorable Solvency: Illumina ended the second quarter of 2026 with combined cash, cash equivalents and short-term investments of $1.04 billion compared with $1.09 billion at the end of the first quarter.
Current debt was $500 million, broadly unchanged sequentially, while long-term debt remained at $1.49 billion. Gross debt was approximately 1.6 times last-12-month EBITDA, reflecting manageable leverage. The company’s liquidity remains sufficient to support operations, strategic investments and capital returns.
What Ails ILMN Stock?Macroeconomic Cost Risks Remain: Illumina continues to operate in a higher-cost environment shaped by tariffs, freight and component inflation. In the second quarter of 2026, adjusted gross margin was 68.2%, down 120 bps year over year, as a heavier instrument mix, higher freight and memory costs, and lower-margin SomaLogic revenues offset operating initiatives and lower tariff costs. Adjusted operating margin was 22.5%, down 130 bps year over year. Tariffs, shipping costs and memory costs are expected to continue affecting results, leaving margins sensitive to product mix and external cost volatility.
ILMN Stock Estimate TrendThe Zacks Consensus Estimate for ILMN’s 2026 EPS has increased 2.3% to $5.34 in the past 30 days.
The Zacks Consensus Estimate for the company’s 2026 revenues is pegged at $4.62 billion, calling for a 6.4% rise from the year-ago reported number.
Other Key PicksSome other top-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and Teleflex (TFX - Free Report) .
Globus Medical has an earnings yield of 5.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED’s shares have rallied 42.3% against the industry’s 6.3% decline over the past year.
GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Veracyte, sporting a Zacks Rank #1 at present, has an earnings yield of 4.6% against the industry’s negative 1.7% yield. Shares of the company have risen 38% against the industry’s 6.3% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
Teleflex, carrying a Zacks Rank #2 at present, has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 12.8% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX’s shares have rallied 5% against the industry’s 6.2% decline over the past year.
Biondo Investment Advisors LLC bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 10,630 shares of the life sciences company’s stock, valued at approximately $1,869,000.
Several other institutional investors and hedge funds have also bought and sold shares of ILMN. Keating Financial Advisory Services Inc. purchased a new position in shares of Illumina in the second quarter worth $32,000. Rakuten Securities Inc. bought a new stake in Illumina during the 2nd quarter valued at $33,000. Elyxium Wealth LLC purchased a new stake in Illumina during the 4th quarter valued at $25,000. TD Waterhouse Canada Inc. purchased a new stake in Illumina during the 4th quarter valued at $26,000. Finally, Laurel Wealth Advisors LLC bought a new stake in Illumina in the 4th quarter worth $26,000. 89.42% of the stock is currently owned by institutional investors.
Insider Activity In other Illumina news, Director Keith A. Meister sold 457,858 shares of the firm’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the completion of the sale, the director directly owned 2,372,694 shares in the company, valued at approximately $474,776,069.40. This trade represents a 16.18% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Scott D. Ericksen sold 1,500 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $150.10, for a total transaction of $225,150.00. Following the completion of the transaction, the chief accounting officer owned 14,946 shares of the company’s stock, valued at approximately $2,243,394.60. The trade was a 9.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 2,095,958 shares of company stock worth $401,720,974 over the last three months. 2.90% of the stock is currently owned by corporate insiders.
Analyst Upgrades and Downgrades A number of research firms have issued reports on ILMN. Zacks Research upgraded shares of Illumina from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 3rd. Barclays upped their price target on Illumina from $145.00 to $160.00 and gave the company an “underweight” rating in a research report on Friday, July 31st. Wall Street Zen upgraded Illumina from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Citigroup lifted their price objective on Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a research report on Monday, August 3rd. Finally, TD Cowen boosted their target price on Illumina from $192.00 to $210.00 and gave the company a “hold” rating in a research note on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $188.40. Check Out Our Latest Research Report on ILMN
Illumina Price Performance Shares of NASDAQ ILMN opened at $219.40 on Monday. Illumina, Inc. has a 1 year low of $88.00 and a 1 year high of $220.43. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The company’s 50-day moving average is $188.01 and its 200 day moving average is $152.52. The stock has a market capitalization of $33.13 billion, a P/E ratio of 40.93, a P/E/G ratio of 3.09 and a beta of 1.44.
Illumina (NASDAQ:ILMN – Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.08. The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The firm’s revenue was up 9.4% on a year-over-year basis. During the same period in the previous year, the company posted $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, sell-side analysts expect that Illumina, Inc. will post 5.36 earnings per share for the current year.
Key Headlines Impacting Illumina Here are the key news stories impacting Illumina this week:
Positive Sentiment: Illumina’s latest quarterly results exceeded expectations, with earnings of $1.31 per share versus the $1.23 consensus estimate and revenue of $1.16 billion versus expectations of $1.13 billion. Revenue increased 9.4% year over year, while fiscal 2026 EPS guidance remains $5.30-$5.40. Illumina stock information Positive Sentiment: Several institutional investors increased their positions, including Marshall Wace, Cresset Asset Management and Empowered Funds. Hedge funds and other institutions collectively own approximately 89.4% of ILMN shares, indicating strong professional-investor participation. Neutral Sentiment: Analyst opinions remain mixed. Zacks Research upgraded the stock to “strong buy,” and Leerink Partners raised its target to $210, while Deutsche Bank downgraded the shares to “hold.” The overall consensus rating is “hold,” with an average target of $188.40—below recent trading levels. Analyst coverage of Illumina Negative Sentiment: Director Keith A. Meister sold 679,574 Illumina shares from August 19 through August 21 for approximately $145.6 million. The transactions reduced his ownership by roughly one-third, although he still holds about 1.41 million shares. The size and timing of the sales may raise concerns about insider conviction, even though the filings do not establish the reason for the transactions. SEC insider ownership filing Negative Sentiment: SVP Christensen Jakob Wedel also sold 1,033 shares under a pre-arranged Rule 10b5-1 trading plan. The smaller, planned transaction is less concerning than Meister’s sales but adds to the recent pattern of insider selling. Illumina insider trading alert Illumina Company Profile (Free Report)
Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.
Read More Five stocks we like better than Illumina VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
Allworth Financial LP acquired a new position in Illumina, Inc. (NASDAQ:ILMN – Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 5,976 shares of the life sciences company’s stock, valued at approximately $1,051,000.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in ILMN. BlackRock Inc. bought a new stake in Illumina in the 2nd quarter worth about $3,374,423,000. Plato Investment Management Ltd bought a new position in Illumina during the 2nd quarter valued at about $948,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Illumina during the 2nd quarter valued at about $30,501,000. Edmond DE Rothschild Holding S.A. purchased a new stake in shares of Illumina during the 2nd quarter valued at about $129,792,000. Finally, Impact Partnership Wealth LLC boosted its holdings in shares of Illumina by 235.8% during the 1st quarter. Impact Partnership Wealth LLC now owns 11,080 shares of the life sciences company’s stock valued at $1,366,000 after acquiring an additional 7,780 shares during the last quarter. 89.42% of the stock is owned by institutional investors.
Insider Activity at Illumina In other Illumina news, SVP Patricia Leckman sold 783 shares of Illumina stock in a transaction on Friday, June 5th. The shares were sold at an average price of $162.59, for a total value of $127,307.97. Following the sale, the senior vice president directly owned 21,259 shares in the company, valued at approximately $3,456,500.81. The trade was a 3.55% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 1,033 shares of Illumina stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the sale, the senior vice president directly owned 14,023 shares in the company, valued at $2,685,684.96. This trade represents a 6.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 2,095,958 shares of company stock worth $401,720,974. 2.90% of the stock is currently owned by corporate insiders.
Illumina Stock Performance Shares of ILMN opened at $219.40 on Friday. The business has a 50-day simple moving average of $188.01 and a two-hundred day simple moving average of $152.44. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. Illumina, Inc. has a 52 week low of $88.00 and a 52 week high of $220.43. The stock has a market cap of $33.13 billion, a price-to-earnings ratio of 40.93, a PEG ratio of 3.09 and a beta of 1.45. Illumina (NASDAQ:ILMN – Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. The firm had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business’s quarterly revenue was up 9.4% on a year-over-year basis. During the same period in the previous year, the firm earned $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, analysts expect that Illumina, Inc. will post 5.36 EPS for the current year.
Key Stories Impacting Illumina Here are the key news stories impacting Illumina this week:
Positive Sentiment: Illumina’s latest quarterly results exceeded expectations, with earnings of $1.31 per share versus the $1.23 consensus estimate and revenue of $1.16 billion versus expectations of $1.13 billion. Revenue increased 9.4% year over year, while fiscal 2026 EPS guidance remains $5.30-$5.40. Illumina stock information Positive Sentiment: Several institutional investors increased their positions, including Marshall Wace, Cresset Asset Management and Empowered Funds. Hedge funds and other institutions collectively own approximately 89.4% of ILMN shares, indicating strong professional-investor participation. Neutral Sentiment: Analyst opinions remain mixed. Zacks Research upgraded the stock to “strong buy,” and Leerink Partners raised its target to $210, while Deutsche Bank downgraded the shares to “hold.” The overall consensus rating is “hold,” with an average target of $188.40—below recent trading levels. Analyst coverage of Illumina Negative Sentiment: Director Keith A. Meister sold 679,574 Illumina shares from August 19 through August 21 for approximately $145.6 million. The transactions reduced his ownership by roughly one-third, although he still holds about 1.41 million shares. The size and timing of the sales may raise concerns about insider conviction, even though the filings do not establish the reason for the transactions. SEC insider ownership filing Negative Sentiment: SVP Christensen Jakob Wedel also sold 1,033 shares under a pre-arranged Rule 10b5-1 trading plan. The smaller, planned transaction is less concerning than Meister’s sales but adds to the recent pattern of insider selling. Illumina insider trading alert Analyst Ratings Changes A number of brokerages have recently commented on ILMN. Guggenheim lifted their price target on shares of Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Sanford C. Bernstein restated a “market perform” rating and set a $215.00 price objective on shares of Illumina in a research report on Friday, July 31st. Leerink Partners increased their price target on Illumina from $175.00 to $210.00 and gave the company an “outperform” rating in a report on Friday, July 17th. Deutsche Bank Aktiengesellschaft downgraded Illumina to a “hold” rating in a research note on Wednesday, August 5th. Finally, Barclays lifted their price objective on Illumina from $145.00 to $160.00 and gave the stock an “underweight” rating in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Illumina has an average rating of “Hold” and a consensus target price of $188.40.
Read Our Latest Research Report on Illumina
Illumina Profile (Free Report)
Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.
See Also Five stocks we like better than Illumina 2 Biotech Stocks Shaping Up for Major Breakouts 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit? Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in ILMN over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either BioMarin Pharmaceutical (BMRN - Free Report) or Illumina (ILMN - Free Report) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.
We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.
BioMarin Pharmaceutical and Illumina are both sporting a Zacks Rank of #2 (Buy) right now. The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that both of these companies have improving earnings outlooks. But this is only part of the picture for value investors.
Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels.
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.
BMRN currently has a forward P/E ratio of 14.02, while ILMN has a forward P/E of 36.10. We also note that BMRN has a PEG ratio of 0.41. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. ILMN currently has a PEG ratio of 2.72.
Another notable valuation metric for BMRN is its P/B ratio of 2.13. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, ILMN has a P/B of 10.26.
These metrics, and several others, help BMRN earn a Value grade of B, while ILMN has been given a Value grade of C.
Both BMRN and ILMN are impressive stocks with solid earnings outlooks, but based on these valuation figures, we feel that BMRN is the superior value option right now.
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
#1 (Strong Buy) stocks have produced an unmatched +23.94% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Illumina (ILMN - Free Report) San Diego, CA.-based Illumina Inc. provides sequencing and array-based solutions for genetic and genomic analysis. The products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. Its customers include leading genomic research centers, academic institutions, government laboratories, hospitals as well as pharmaceutical, biotechnology, commercial molecular diagnostic and consumer genomics companies.
ILMN is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.
Additionally, the company could be a top pick for growth investors. ILMN has a Growth Style Score of B, forecasting year-over-year earnings growth of 10.3% for the current fiscal year.
For fiscal 2026, seven analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.17 to $5.34 per share. ILMN boasts an average earnings surprise of +9.7%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, ILMN should be on investors' short list.
Empowered Funds LLC raised its stake in Illumina, Inc. (NASDAQ:ILMN – Free Report) by 104.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,996 shares of the life sciences company’s stock after purchasing an additional 6,633 shares during the period. Empowered Funds LLC’s holdings in Illumina were worth $1,602,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also modified their holdings of the company. Impact Partnership Wealth LLC grew its position in shares of Illumina by 235.8% during the first quarter. Impact Partnership Wealth LLC now owns 11,080 shares of the life sciences company’s stock worth $1,366,000 after acquiring an additional 7,780 shares during the last quarter. Louisiana State Employees Retirement System acquired a new stake in Illumina in the first quarter valued at $5,460,000. SG Americas Securities LLC increased its stake in Illumina by 8.0% in the 1st quarter. SG Americas Securities LLC now owns 86,318 shares of the life sciences company’s stock valued at $10,640,000 after purchasing an additional 6,425 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al grew its position in shares of Illumina by 27.4% in the fourth quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 348,011 shares of the life sciences company’s stock valued at $45,645,000 after purchasing an additional 74,900 shares during the last quarter. Finally, New York State Teachers Retirement System boosted its stake in shares of Illumina by 2.7% during the 4th quarter. New York State Teachers Retirement System now owns 149,638 shares of the life sciences company’s stock worth $19,627,000 after purchasing an additional 4,002 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.
Insiders Place Their Bets In other news, CAO Scott D. Ericksen sold 1,500 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $150.10, for a total transaction of $225,150.00. Following the completion of the transaction, the chief accounting officer owned 14,946 shares of the company’s stock, valued at approximately $2,243,394.60. This represents a 9.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 457,858 shares of the company’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total value of $91,617,385.80. Following the completion of the transaction, the director directly owned 2,372,694 shares of the company’s stock, valued at approximately $474,776,069.40. This trade represents a 16.18% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 1,744,811 shares of company stock worth $303,897,291 over the last quarter. 2.90% of the stock is currently owned by company insiders.
Illumina Stock Performance ILMN stock opened at $187.96 on Friday. Illumina, Inc. has a 12 month low of $88.00 and a 12 month high of $207.00. The firm has a 50 day moving average of $181.13 and a two-hundred day moving average of $149.05. The company has a market capitalization of $28.38 billion, a price-to-earnings ratio of 35.07, a P/E/G ratio of 2.73 and a beta of 1.45. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53.
Illumina (NASDAQ:ILMN – Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter in the prior year, the company posted $1.19 EPS. The firm’s revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities analysts anticipate that Illumina, Inc. will post 5.36 EPS for the current fiscal year.
Key Stories Impacting Illumina Here are the key news stories impacting Illumina this week:
Positive Sentiment: Zacks upgraded Illumina to Rank #1, or “Strong Buy,” citing improving earnings prospects and strong momentum characteristics. The upgrade could attract near-term buying interest. What Makes Illumina a New Strong Buy Stock Positive Sentiment: Illumina’s latest quarterly results provide a supportive backdrop: earnings per share exceeded estimates, revenue topped forecasts, and sales increased 9.4% year over year. The company continues to guide to fiscal 2026 EPS of $5.30 to $5.40. Recent bullish analysts have raised price targets as high as $230. Illumina Earnings and Analyst Information Neutral Sentiment: Analyst opinion remains divided. Although several firms maintain Buy or Outperform ratings, the consensus rating is “Hold,” with an average price target of $188.40—close to recent trading levels—suggesting limited consensus upside. Negative Sentiment: Director Keith A. Meister sold 741,127 shares across August 4 and 5 for approximately $148.2 million, reducing his position by about 28%. He retains more than 2 million shares, but the size of the transactions may pressure sentiment and raise concerns about insider confidence. Illumina Insider Trading Filing Negative Sentiment: Bank of America Securities reiterated its “Sell” rating and $140 price target, arguing that a one-time consumables benefit may be masking weak underlying demand. The target is well below recent levels, highlighting valuation and sustainability concerns. Bank of America Maintains Sell Rating Wall Street Analyst Weigh In Several research firms have issued reports on ILMN. Wall Street Zen upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Guggenheim lifted their target price on Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Canaccord Genuity Group increased their price target on Illumina from $190.00 to $205.00 and gave the stock a “hold” rating in a research report on Monday. Daiwa Securities Group raised shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price for the company in a research note on Thursday, May 14th. Finally, Royal Bank Of Canada raised their price target on Illumina from $170.00 to $230.00 and gave the company an “outperform” rating in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $188.40.
Read Our Latest Analysis on Illumina
Illumina Company Profile (Free Report)
Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.
Read More Five stocks we like better than Illumina Datadog’s Drop Says More About Expectations Than Earnings D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEKeros Therapeutics, Inc. $KROS Shares Acquired by Empowered Funds LLC
NEXT HEADLINE »Cetera Investment Advisers Has $2.54 Million Stake in Innovator U.S. Equity Ultra Buffer ETF – December $UDEC
Illumina (ILMN - Free Report) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.
The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.
The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.
As such, the Zacks rating upgrade for Illumina is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.
Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.
For Illumina, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.
Harnessing the Power of Earnings Estimate RevisionsAs empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .
Earnings Estimate Revisions for IlluminaFor the fiscal year ending December 2026, this genetic testing tools company is expected to earn $5.34 per share, which is unchanged compared with the year-ago reported number.
Analysts have been steadily raising their estimates for Illumina. Over the past three months, the Zacks Consensus Estimate for the company has increased 3%.
Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
You can learn more about the Zacks Rank here >>>
The upgrade of Illumina to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Illumina (ILMN - Free Report) San Diego, CA.-based Illumina Inc. provides sequencing and array-based solutions for genetic and genomic analysis. The products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. Its customers include leading genomic research centers, academic institutions, government laboratories, hospitals as well as pharmaceutical, biotechnology, commercial molecular diagnostic and consumer genomics companies.
ILMN is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.
Momentum investors should take note of this Medical stock. ILMN has a Momentum Style Score of A, and shares are up 6.4% over the past four weeks.
Seven analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.17 to $5.34 per share. ILMN also boasts an average earnings surprise of +9.7%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, ILMN should be on investors' short list.
Shares of Illumina (ILMN - Free Report) have been strong performers lately, with the stock up 8.7% over the past month. The stock hit a new 52-week high of $205.93 in the previous session. Illumina has gained 56.4% since the start of the year compared to the 0.1% gain for the Zacks Medical sector and the 2% return for the Zacks Medical - Biomedical and Genetics industry.
What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, having beaten the Zacks Consensus Estimate in each of the last four quarters. In its last earnings report on July 30, 2026, Illumina reported EPS of $1.31 versus consensus estimate of $1.23 while it beat the consensus revenue estimate by 3.36%.
For the current fiscal year, Illumina is expected to post earnings of $5.28 per share on $4.56 in revenues. This represents a 9.09% change in EPS on a 5.09% change in revenues. For the next fiscal year, the company is expected to earn $5.99 per share on $4.86 in revenues. This represents a year-over-year change of 13.45% and 6.56%, respectively.
Valuation MetricsIllumina may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company has run ahead of itself.
On this front, we can look at the Zacks Style Scores, as they provide investors with an additional way to sort through stocks (beyond looking at the Zacks Rank of a security). The individual style scores for Value, Growth, Momentum and the combined VGM Score run from A through F. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style.
Illumina has a Value Score of C. The stock's Growth and Momentum Scores are B and B, respectively, giving the company a VGM Score of B.
In terms of its value breakdown, the stock currently trades at 38.9X current fiscal year EPS estimates, which is a premium to the peer industry average of 20.8X. On a trailing cash flow basis, the stock currently trades at 30.5X versus its peer group's average of 12.9X. Additionally, the stock has a PEG ratio of 2.99. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.
Zacks RankWe also need to consider the stock's Zacks Rank, as this is even more important than the company's VGM Score. Fortunately, Illumina currently has a Zacks Rank of #2 (Buy) thanks to favorable earnings estimate revisions from covering analysts.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Illumina passes the test. Thus, it seems as though Illumina shares could still be poised for more gains ahead.
How Does ILMN Stack Up to the Competition?Shares of ILMN have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is NeoGenomics, Inc. (NEO - Free Report) . NEO has a Zacks Rank of #1 (Strong Buy) and a Value Score of D, a Growth Score of B, and a Momentum Score of D.
Earnings were strong last quarter. NeoGenomics, Inc. beat our consensus estimate by 66.67%, and for the current fiscal year, NEO is expected to post earnings of $0.18 per share on revenue of $802.67 million.
Shares of NeoGenomics, Inc. have gained 0.9% over the past month, and currently trade at a forward P/E of 87.37X and a P/CF of 45.64X.
The Medical - Biomedical and Genetics industry is in the top 37% of all the industries we have in our universe, so it looks like there are some nice tailwinds for ILMN and NEO, even beyond their own solid fundamental situation.
Illumina (ILMN - Free Report) came out with quarterly earnings of $1.31 per share, beating the Zacks Consensus Estimate of $1.23 per share. This compares to earnings of $1.19 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +6.50%. A quarter ago, it was expected that this genetic testing tools company would post earnings of $1.05 per share when it actually produced earnings of $1.15, delivering a surprise of +9.52%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Illumina, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $1.16 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 3.36%. This compares to year-ago revenues of $1.06 billion. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Illumina shares have added about 48.5% since the beginning of the year versus the S&P 500's gain of 6.9%.
What's Next for Illumina?While Illumina has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Illumina was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.35 on $1.13 billion in revenues for the coming quarter and $5.22 on $4.56 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Ocugen (OCGN - Free Report) , has yet to report results for the quarter ended June 2026. The results are expected to be released on August 6.
This biotech knee implant developer is expected to post quarterly loss of $0.05 per share in its upcoming report, which represents no change from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Ocugen's revenues are expected to be $1.4 million, up 2.2% from the year-ago quarter.
Illumina (ILMN - Free Report) reported $1.16 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 9.4%. EPS of $1.31 for the same period compares to $1.19 a year ago.
The reported revenue represents a surprise of +3.36% over the Zacks Consensus Estimate of $1.12 billion. With the consensus EPS estimate being $1.23, the EPS surprise was +6.5%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Illumina performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenue by Source- Total product revenue- Sequencing: $900 million versus the four-analyst average estimate of $881.98 million. The reported number represents a year-over-year change of +7.7%.Revenue- Product revenue- Total Consumable: $852 million versus $844.76 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +5.1% change.Revenue- Service and other revenue: $177 million versus the three-analyst average estimate of $162.77 million. The reported number represents a year-over-year change of +20.4%.Revenue- Product revenue: $982 million compared to the $965.46 million average estimate based on three analysts. The reported number represents a change of +7.7% year over year.Revenue- Product revenue- Total Instruments: $130 million compared to the $120.7 million average estimate based on three analysts. The reported number represents a change of +28.7% year over year.Revenue- Consumables- Microarrays: $77 million versus the two-analyst average estimate of $79.2 million. The reported number represents a year-over-year change of +8.5%.Revenue- Instruments- Sequencing: $125 million versus $118.04 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +30.2% change.Revenue- Consumables- Sequencing: $775 million compared to the $763.94 million average estimate based on two analysts. The reported number represents a change of +4.7% year over year.Revenue- Instruments- Microarrays: $5 million versus $4.02 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a 0% change.Revenue by Source- Total product revenue- Microarray: $82 million versus $83.21 million estimated by two analysts on average.View all Key Company Metrics for Illumina here>>>
Shares of Illumina have returned +5.9% over the past month versus the Zacks S&P 500 composite's -1.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
, /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the second quarter of fiscal year 2026.
Second quarter 2026 results
Revenue of $1.16 billion for Q2 2026, up 9.5% from Q2 2025 and up 8.1% excluding the impacts of currency, acquisitions, and China ("ROW1 organic revenue growth") GAAP operating margin of 21.1% and non-GAAP operating margin of 22.5% GAAP diluted EPS of $1.35 and non-GAAP diluted EPS of $1.31 "Illumina delivered strong results during the second quarter. Momentum continued to build through the first half of 2026, as our technology is enabling clinical customers to expand sequencing-intensive applications. Based on this performance, we are increasing our revenue and earnings guidance for the year," said Jacob Thaysen, Chief Executive Officer of Illumina. "Demand for NovaSeq X remains high as we expand our workflow and multiomics capabilities, broadening the value of Illumina's ecosystem."
Fiscal year 2026 guidance
For fiscal year 2026, we now expect:
Total revenue of $4.60-$4.64 billion, versus prior guidance of $4.52-$4.62 billion ROW organic revenue growth greater than 5%, versus prior guidance of 2%-4% Non-GAAP operating margin of 23.4%-23.6%, unchanged from prior guidance Non-GAAP diluted EPS of $5.30-$5.40, versus prior guidance of $5.15-$5.30 Second quarter results
GAAP
Non-GAAP (a)
Dollars in millions, except per share amounts
Q2 2026
Q2 2025
Q2 2026
Q2 2025
Revenue
$ 1,159
$ 1,059
$ 1,159
$ 1,059
Gross margin
66.4 %
65.6 %
68.2 %
69.4 %
Operating profit
$ 245
$ 214
$ 260
$ 252
Operating margin
21.1 %
20.2 %
22.5 %
23.8 %
Diluted EPS
$ 1.35
$ 1.49
$ 1.31
$ 1.19
(a)
See tables in "Results of Operations - Non-GAAP" section below for GAAP and non-GAAP reconciliations.
Capital expenditures for free cash flow purposes were $39 million for Q2 2026. Cash flow provided by operations was $201 million, compared to $234 million in the prior year period. Free cash flow (cash flow provided by operations less capital expenditures) was $162 million for the quarter, compared to $204 million in the prior year period. Depreciation and amortization expense was $70 million for Q2 2026. At the close of the quarter, the company held $1.17 billion in cash, cash equivalents and short-term investments.
____________________
1
ROW = rest-of-world, excluding Greater China region due to our inclusion on China's Unreliable Entities List
Conference call information
The conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, July 30, 2026. Interested parties may access the live webcast via the Investor Info section of Illumina's website or directly through the following link - https://illumina-earnings-call-q2-2026.open-exchange.net/. To ensure timely connection, please join at least ten minutes before the scheduled start of the call. A replay of the conference call will be posted on Illumina's website after the event and will be available for at least 30 days following.
Statement regarding use of non-GAAP financial measures
The company reports non-GAAP results for diluted earnings per share, gross margin, operating margin, and free cash flow, among others, in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The company's financial measures under GAAP include substantial charges such as amortization of acquired intangible assets, among others, that are listed in the reconciliations of GAAP and non-GAAP financial measures included in this press release. Management has excluded the effects of these items in non-GAAP measures to assist investors in analyzing and assessing past and future operating performance. Non-GAAP operating margin and diluted earnings per share are key components of the financial metrics utilized by the company's board of directors to measure, in part, management's performance and determine significant elements of management's compensation. The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP results are presented in this release.
The company provides forward-looking guidance on a non-GAAP basis. The company is unable to provide a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures because it is unable to predict with reasonable certainty the impact of items such as acquisition-related costs, fair value adjustments to contingent consideration, gains and losses from strategic investments, asset impairments, restructuring activities, and the ultimate outcome of pending litigation, among others, without unreasonable effort. These items are uncertain, inherently difficult to predict, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For the same reasons, the company is unable to address the significance of the unavailable information, which could be material to future results.
Use of forward-looking statements
This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) changes in the rate of growth in the markets we serve, including the proteomics market; (ii) the volume, timing and mix of customer orders among our products and services; (iii) our ability to adjust our operating expenses to align with our revenue expectations; (iv) our ability to successfully integrate SomaLogic, Inc. and certain other assets we acquired from Standard BioTools Inc. (the SomaLogic Business) into our existing operations and the SomaLogic Business' technology and products into our portfolio; (v) our ability to successfully manage partner and customer relationships in the proteomics market; (vi) uncertainty regarding the impact of our inclusion on the "unreliable entities list" by regulatory authorities in China; (vii) uncertainty regarding tariffs imposed or threatened by the U.S. government and its trading partners, related court proceedings or administrative actions (including potential refund or relief programs), and other possible tariffs or trade protection measures and our efforts to mitigate the impact of such tariffs; (viii) our ability to manufacture robust instrumentation and consumables, including the SomaLogic Business' products; (ix) the success of products and services competitive with our own; (x) challenges inherent in developing, manufacturing, and launching new products and services, including expanding or modifying manufacturing operations and reliance on third-party suppliers for critical components; (xi) the impact of recently launched or pre-announced products and services on existing products and services; (xii) our ability to modify our business strategies to accomplish our desired operational goals; (xiii) our ability to realize the anticipated benefits from prior or future actions to streamline and improve our R&D processes, reduce our operating expenses and maximize our revenue growth; (xiv) our ability to further develop and commercialize our instruments, consumables, and products; (xv) our ability to deploy new products, services, and applications, and to expand the markets for our technology platforms; (xvi) the risk of additional litigation arising against us in connection with the GRAIL acquisition; (xvii) our ability to obtain approval by third-party payors to reimburse patients for our products; (xviii) our ability to obtain regulatory clearance for our products from government agencies; (xix) our ability to successfully partner with other companies and organizations to develop new products, expand markets, and grow our business; (xx) uncertainty, or adverse economic and business conditions, including as a result of slowing or uncertain economic growth or armed conflict; (xxi) the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments; and (xxii) legislative, regulatory and economic developments, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Illumina, Inc.
Condensed Consolidated Balance Sheets
(In millions)
June 28,
2026
December 28,
2025
ASSETS
(unaudited)
Current assets:
Cash and cash equivalents
$ 1,040
$ 1,418
Short-term investments
128
215
Accounts receivable, net
764
854
Inventory, net
629
564
Prepaid expenses and other current assets
273
238
Total current assets
2,834
3,289
Property and equipment, net
745
759
Operating lease right-of-use assets
362
370
Goodwill
1,284
1,113
Intangible assets, net
410
210
Deferred tax assets, net
439
454
Other assets
576
449
Total assets
$ 6,650
$ 6,644
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable
$ 230
$ 240
Accrued liabilities
848
846
Term debt, current portion
500
499
Total current liabilities
1,578
1,585
Operating lease liabilities
454
486
Term debt
1,491
1,490
Other long-term liabilities
289
360
Stockholders' equity
2,838
2,723
Total liabilities and stockholders' equity
$ 6,650
$ 6,644
Illumina, Inc.
Condensed Consolidated Statements of Operations
(In millions, except per share amounts)
(unaudited)
Three Months Ended
Six Months Ended
June 28,
2026
June 29,
2025
June 28,
2026
June 29,
2025
Revenue:
Product revenue
$ 982
$ 912
$ 1,899
$ 1,793
Service and other revenue
177
147
352
307
Total revenue
1,159
1,059
2,251
2,100
Cost of revenue:
Cost of product revenue
291
276
565
529
Cost of service and other revenue
80
71
160
160
Amortization of acquired intangible assets
18
17
35
33
Total cost of revenue
389
364
760
722
Gross profit
770
695
1,491
1,378
Operating expense:
Research and development
252
247
492
499
Selling, general and administrative
273
234
545
501
Total operating expense
525
481
1,037
1,000
Income from operations
245
214
454
378
Other income (expense), net
15
92
(37)
110
Income before income taxes
260
306
417
488
Provision for income taxes
53
71
77
122
Net income
$ 207
$ 235
$ 340
$ 366
Earnings per share:
Basic
$ 1.37
$ 1.49
$ 2.24
$ 2.32
Diluted
$ 1.35
$ 1.49
$ 2.22
$ 2.31
Shares used in computing earnings per share:
Basic
151
157
152
158
Diluted
153
157
154
158
Illumina, Inc.
Condensed Statements of Cash Flows
(In millions)
(unaudited)
Three Months Ended
Six Months Ended
June 28,
2026
June 29,
2025
June 28,
2026
June 29,
2025
Net cash provided by operating activities
$ 201
$ 234
$ 490
$ 474
Net cash used in investing activities
(121)
(49)
(488)
(112)
Net cash used in financing activities
(129)
(371)
(380)
(566)
Effect of exchange rate changes on cash and cash equivalents
—
7
—
11
Net decrease in cash and cash equivalents
(49)
(179)
(378)
(193)
Cash and cash equivalents, beginning of period
1,089
1,113
1,418
1,127
Cash and cash equivalents, end of period
$ 1,040
$ 934
$ 1,040
$ 934
Calculation of free cash flow:
Net cash provided by operating activities
$ 201
$ 234
$ 490
$ 474
Purchases of property and equipment
(39)
(30)
(78)
(62)
Free cash flow (a)
$ 162
$ 204
$ 412
$ 412
(a)
Free cash flow, which is a non-GAAP financial measure, is calculated as net cash provided by operating activities reduced by purchases of property and equipment. Free cash flow is useful to management as it is one of the metrics used to evaluate our performance and to compare us with other companies in our industry. However, our calculation of free cash flow may not be comparable to similar measures used by other companies.
Illumina, Inc.
Results of Operations - Non-GAAP
(unaudited)
TABLE 1: RECONCILIATION OF REVENUE GROWTH:
Three Months
Ended
Six Months
Ended
June 28,
2026
June 28,
2026
Revenue growth
9.5 %
7.2 %
Impact of acquisitions
(2.1) %
(1.9) %
Impact of currency exchange rates
(0.9) %
(1.4) %
Organic revenue growth (non-GAAP) (a)
6.5 %
3.9 %
Impact of China
1.6 %
1.9 %
ROW organic revenue growth (non-GAAP) (a)
8.1 %
5.8 %
TABLE 2: RECONCILIATION OF GAAP AND NON-GAAP DILUTED EARNINGS PER SHARE:
Three Months Ended
Six Months Ended
June 28,
2026
June 29,
2025
June 28,
2026
June 29,
2025
GAAP diluted earnings per share
$ 1.35
$ 1.49
$ 2.22
$ 2.31
Acquisition-related costs (d)
0.07
0.03
0.23
0.11
Transformational initiatives (e)
0.03
0.06
0.06
0.26
Strategic investment (gain) loss, net (f)
(0.15)
(0.65)
0.08
(0.85)
Intangible impairment
—
0.15
—
0.15
Other (g)
—
—
—
0.03
Provision for income taxes (h)
0.01
0.11
(0.13)
0.15
Non-GAAP diluted earnings per share (b)
$ 1.31
$ 1.19
$ 2.46
$ 2.16
TABLE 3: RECONCILIATION OF GAAP AND NON-GAAP RESULTS OF OPERATIONS AS A PERCENT OF REVENUE:
Three Months Ended
Six Months Ended
(Dollars in millions)
June 28, 2026
June 29, 2025
June 28, 2026
June 29, 2025
GAAP gross profit (c)
$ 770
66.4 %
$ 695
65.6 %
$ 1,491
66.2 %
$ 1,378
65.6 %
Acquisition-related costs (d)
20
1.8 %
16
1.5 %
43
2.0 %
33
1.6 %
Transformational initiatives (e)
—
— %
1
0.1 %
—
— %
3
0.1 %
Intangible impairment
—
— %
23
2.2 %
—
— %
23
1.1 %
Non-GAAP gross profit (b)
$ 790
68.2 %
$ 735
69.4 %
$ 1,534
68.2 %
$ 1,437
68.4 %
GAAP operating profit
$ 245
21.1 %
$ 214
20.2 %
$ 454
20.2 %
$ 378
18.0 %
Acquisition-related costs (d)
11
1.0 %
5
0.5 %
35
1.6 %
17
0.8 %
Transformational initiatives (e)
4
0.4 %
10
0.9 %
10
0.4 %
41
2.0 %
Intangible impairment
—
— %
23
2.2 %
—
— %
23
1.1 %
Other (g)
—
— %
—
— %
—
— %
5
0.2 %
Non-GAAP operating profit (b)
$ 260
22.5 %
$ 252
23.8 %
$ 499
22.2 %
$ 464
22.1 %
(a)
Organic revenue growth adjusts for the impact from acquisitions and currency movements, which is calculated using comparative prior period foreign exchange rates to translate current period revenue, net of the effects of hedges; Rest of World (ROW) organic revenue growth also adjusts for the impact from our China region.
(b)
Non-GAAP gross profit, included within non-GAAP operating profit, is a key measure of the effectiveness and efficiency of manufacturing processes, product mix and the average selling prices of our products and services. Non-GAAP diluted earnings per share and non-GAAP operating profit exclude the effects of the pro forma adjustments as detailed above. Non-GAAP operating margin and diluted earnings per share are key components of the financial metrics utilized by the company's board of directors to measure, in part, management's performance and determine significant elements of management's compensation. Management has excluded the effects of these items in these measures to assist investors in analyzing and assessing past and future operating performance.
(c)
Reconciling amounts are recorded in cost of revenue.
•
Amounts for Q2 2026 and YTD 2026 consist primarily of:
•
Amortization of intangible assets of $18 million and $35 million (cost of revenue)
•
Amortization of inventory fair value step-up for SomaLogic of $2 million and $8 million (cost of revenue)
•
Expenses for the SomaLogic and GRAIL acquisitions of $7 million and $22 million (operating expense)
•
Net gains on contingent consideration liabilities of ($16) million and ($32) million (operating expense)
Amounts for Q2 2025 and YTD 2025 consist primarily of:
•
Amortization of intangible assets of $16 million and $33 million (cost of revenue)
•
Expenses for the SomaLogic and GRAIL acquisitions of $9 million and $15 million (operating expense)
•
Net gains on contingent consideration liabilities of ($21) million and ($32) million (operating expense)
(e)
Amounts for Q2 2026 and YTD 2026 consist primarily of implementation costs to upgrade our ERP system. Amounts for Q2 2025 and YTD 2025 consist primarily of employee severance costs from restructuring activities.
(f)
Amounts consist of realized and unrealized gains and losses and impairments on our investments.
(g)
Amount consists of $3 million for costs related to board membership changes and $2 million for legal accrual.
(h)
Amounts represent the aggregate of the difference between book and tax accounting related to stock-based compensation cost and the tax impact related to non-GAAP adjustments.
In its upcoming report, Illumina (ILMN - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.23 per share, reflecting an increase of 3.4% compared to the same period last year. Revenues are forecasted to be $1.12 billion, representing a year-over-year increase of 5.9%.
Over the last 30 days, there has been a downward revision of 0.1% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Given this perspective, it's time to examine the average forecasts of specific Illumina metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts forecast 'Revenue by Source- Total product revenue- Sequencing' to reach $881.98 million. The estimate suggests a change of +5.5% year over year.
According to the collective judgment of analysts, 'Revenue- Product revenue- Total Consumable' should come in at $844.76 million. The estimate points to a change of +4.2% from the year-ago quarter.
Analysts expect 'Revenue- Service and other revenue' to come in at $162.77 million. The estimate indicates a change of +10.7% from the prior-year quarter.
The consensus estimate for 'Revenue- Product revenue' stands at $965.46 million. The estimate indicates a change of +5.9% from the prior-year quarter.
It is projected by analysts that the 'Revenue- Product revenue- Total Instruments' will reach $120.70 million. The estimate indicates a change of +19.5% from the prior-year quarter.
Analysts predict that the 'Revenue- Consumables- Microarrays' will reach $79.20 million. The estimate suggests a change of +11.5% year over year.
The consensus among analysts is that 'Revenue- Instruments- Sequencing' will reach $118.04 million. The estimate suggests a change of +23% year over year.
The average prediction of analysts places 'Revenue- Consumables- Sequencing' at $763.94 million. The estimate indicates a year-over-year change of +3.2%.
Based on the collective assessment of analysts, 'Revenue- Instruments- Microarrays' should arrive at $4.02 million. The estimate points to a change of -19.7% from the year-ago quarter.
View all Key Company Metrics for Illumina here>>>
Shares of Illumina have experienced a change of +9.8% in the past month compared to the +1.9% move of the Zacks S&P 500 composite. With a Zacks Rank #2 (Buy), ILMN is expected to outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Sale of Mass Cytometry Business to Multiplex Bio Ensures Full Continuity of CyTOF and Hyperion Product Lines, Customer Relationships, Dedicated Team and Continued Investment in Next Generation Multiplex Platforms
Receives Approximately $30 Million in Negotiated Buyout Related to Contingent Consideration Obligations From Illumina’s Acquisition of SomaLogic Business
BOSTON, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) ("Standard BioTools" or the "Company") today announced the following updates in connection with the Company’s previously announced merger with Treeline Biosciences, Inc. (“Treeline”):
Agreement to sell its Mass Cytometry business to Multiplex Bio, an entity founded and led by advanced imaging industry veterans, Michael Johnson, PhD, Tom Villani, PhD and Charles Coffman;Buyout of the 2026 earnout and all future royalty payments for $30 million related to Illumina, Inc.’s previously completed acquisition of Standard BioTools’ SomaLogic business; andEarly termination of the waiting period by the U.S. Federal Trade Commission under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to the Treeline merger. Sale of Mass Cytometry Business to Multiplex Bio
Multiplex Bio will be focused on the ongoing commercialization of Standard BioTools’ CyTOF and Hyperion product lines and investment in next generation multiplex platforms to advance scientific research. Multiplex Bio intends to maintain the full continuity of the business including all customer relationships, the majority of the Company’s Mass Cytometry team, existing service and maintenance commitments. The business will continue to operate under the Standard BioTools name and brand. Dr. Johnson will serve as Chief Executive Officer, Dr. Villani will serve as Chief Technology Officer and Mr. Coffman will serve as Chief Operating Officer of Multiplex Bio.
Dr. Johnson and Dr. Villani co-founded Visikol, where they pioneered the commercialization of spatial biology tools including 3D microscopy, multiplex tissue imaging and digital pathology services for the world's leading pharmaceutical companies, building Visikol into a recognized leader in advanced tissue imaging before its acquisition by BICO in 2021. Mr. Coffman’s operational and financial background spans building and scaling life science businesses through periods of transition and growth.
Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools, said, “Our Mass Cytometry technology, including the CyTOF and Hyperion instruments, provide unmatched multi-plexing capabilities for biomedical researchers studying a wide range of diseases. After a comprehensive evaluation of opportunities for this business, we are confident that Michael, Tom and Charles are uniquely positioned to steward our products and team given their scientific depth, commercial, operational experience and passion for the technology. Our products will continue to make a meaningful difference in single cell research and in the evolution of spatial biology.”
"The Standard BioTools Mass Cytometry business has an extraordinary scientific legacy and we are honored to carry it forward," said Dr. Johnson. "CyTOF and Hyperion have been foundational to the field of multiplex proteomic detection, and our goal is to build on that foundation and dedicate ourselves fully to advancing these platforms and supporting the scientists who depend on them every day. Our team has operated this technology firsthand and we understand deeply what it means to the customers and researchers who rely on it. We are genuinely excited by what lies ahead for this business and the broader field of multiplex proteomic imaging and detection where we strongly believe Standard BioTools’s products and team are positioned to lead the entire field."
The transaction is valued at up to $10 million, comprising a seller’s note issued by Multiplex Bio to Standard BioTools and a potential milestone payment. Standard BioTools has agreed to provide Multiplex Bio with a working capital loan of up to $10 million at the closing of the transaction.
The transaction is expected to close by the end of 2026, substantially concurrently with the closing of the Treeline transaction, subject to approval by Standard BioTools’ stockholders and other customary closing conditions.
Illumina Earnout and Royalty Buyout Payment
Standard BioTools received approximately $30 million as a buyout of the 2026 earnout and all accrued and unpaid royalty payments related to Illumina, Inc.’s previously completed acquisition of Standard BioTools’ SomaLogic business. This payment will now be included in Standard BioTools’ pro forma net cash position at closing of the Treeline transaction, which will be used in determining the value of Standard BioTools in the exchange ratio in the Treeline transaction, in each case subject to the terms of the merger agreement with Treeline.
Pending Transaction with Treeline
On July 20, 2026, Standard BioTools filed its registration statement on Form S-4 with the U.S. Securities and Exchange Commission. On July 21, 2026, the U.S. Federal Trade Commission provided early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
The Company expects the Treeline transaction to close by the end of 2026, subject to approval by Standard BioTools stockholders and other customary closing conditions.
About Standard BioTools Inc.
Standard BioTools, Inc. (NASDAQ: LAB), is committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world class management team. The Company's established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.
For Research Use Only. Not for use in diagnostic procedures.
Limited Use Label License and other terms may apply: standardbio.com/legal/terms-and-conditions/. Patent and License Information: standardbio.com/legal/notices.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the disposition of the Mass Cytometry business; the expected timing of the disposition of the Mass Cytometry business; the Treeline transaction; the expected timing of the closing of the Treeline transaction; the potential benefits of the Treeline transaction; the prospective performance and outlook of the combined company’s business, performance and opportunities; as well as any assumptions underlying any of the foregoing. The words “advance,” “build,” “lead,” “may,” “will,” “continue,” “commitment,” “expect,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks, uncertainties, and assumptions.
Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, risks and uncertainties related to: (i) the risk that the sale of the Mass Cytometry business may not be completed in a timely manner or at all; (ii) the ability to obtain the requisite approval for the sale of the Mass Cytometry business from stockholders of Standard BioTools; (iii) the possibility that any or all of the various conditions to the consummation of the sale of the Mass Cytometry business may not be satisfied or waived; (iv) the occurrence of any event, change or other circumstance that could give rise to the termination of the agreement relating to the sale of the Mass Cytometry business; (v) the risk that the Treeline transaction may not be completed in a timely manner or at all; (vi) the ability to obtain the requisite approval for the sale of the Treeline transaction from stockholders of Standard BioTools; (vii) the possibility that competing offers or acquisition proposals will be made with respect to the Treeline business; (viii) the possibility that any or all of the various conditions to the consummation of the Treeline transaction may not be satisfied or waived; (ix) the occurrence of any event, change or other circumstance that could give rise to the termination of the Treeline transaction, including in circumstances that would require Standard BioTools to pay a termination fee or other expenses; (x) the effect of the pendency of the Treeline transaction on the parties’ ability to retain and hire key personnel, their ability to maintain relationships with customers, suppliers and others with whom they do business, their business generally or their stock price; (xi) risks related to diverting management’s attention from ongoing business operations or the loss of one or more members of the management team; (xii) the risk that stockholder litigation in connection with either the sale of the Mass Cytometry business or the Treeline transaction may result in significant costs of defense, indemnification and liability; (xiii) the parties’ ability to realize the anticipated benefits of the Treeline transaction; (xiv) the risk that the parties may assume unexpected liabilities and expenses as a result of the Treeline transaction; (xv) the risk that the potential disposition of Standard BioTools’ Microfluidics business may not be completed on favorable terms or at all; (xvi) the risk that Standard BioTools could fail to maintain the listing of its common stock on Nasdaq; (xvii) uncertainties as to the potential for development, commercialization and other benefits of any of Treeline’s product candidates; and (xviii) uncertainties as to Treeline’s anticipated preclinical and clinical drug development activities and related timelines, including the expected timing for commencing clinical trials and announcing data and other clinical results.
For information regarding other related risks, see the “Risk Factors” section of Standard BioTools’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 16, 2026, Standard BioTools’ most recent Quarterly Report on Form 10-Q and Standard BioTools’ other filings with the SEC. Should any of these risks or uncertainties materialize, actual results could differ materially from expectations. These forward-looking statements speak only as of the date hereof. Standard BioTools does not assume any obligation to, and does not currently intend to, update any such forward-looking statements except as may be required by law.
Additional Information and Where to Find It
This communication may be deemed to be solicitation material in respect of Standard BioTools’ sale of its Mass Cytometry business and/or in respect of the Treeline transaction. In connection with the Treeline transaction and related stockholder vote, Standard BioTools has filed with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4 on July 20, 2026 that included a preliminary proxy statement and a preliminary prospectus of Standard BioTools, and that may be amended or supplemented from time to time. In connection with the disposition of the Mass Cytometry business and related stockholder vote, Standard BioTools will file a preliminary proxy statement with the SEC. This communication is not a substitute for the preliminary proxy statement, preliminary prospectus or any other document that Standard BioTools may file with the SEC or send to its stockholders in connection with the proposed transactions. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended. Any definitive proxy statement/prospectus (if and when available) will be mailed to stockholders of Standard BioTools.
INVESTORS AND STOCKHOLDERS OF STANDARD BIOTOOLS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS (INCLUDING ALL AMENDMENTS, SUPPLEMENTS AND ANY DOCUMENTS INCORPORATED BY REFERENCE THEREIN) AND OTHER RELEVANT MATERIALS FILED OR TO BE FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BEFORE MAKING ANY VOTING DECISION WITH RESPECT TO THE PROPOSED TRANSACTIONS BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT STANDARD BIOTOOLS, TREELINE AND THE PROPOSED TRANSACTIONS. Copies of the materials filed or to be filed by Standard BioTools with the SEC may be obtained free of charge on Standard BioTools’ Investor Relations website at https://investors.standardbio.com or by contacting Standard BioTools’ Investor Relations department at [email protected]. In addition, all of those materials will be available at no charge on the SEC’s website at www.sec.gov.
Participants in the Solicitation
Standard BioTools, Treeline and certain of their respective directors, executive officers, other members of management and employees may be deemed to be participants in the solicitation of proxies of Standard BioTools stockholders in connection with the proposed transactions under SEC rules. Investors and stockholders may obtain more detailed information regarding the names, affiliations and interests of Standard BioTools’ executive officers and directors who may, under SEC rules, be deemed participants in the solicitation by reading Standard BioTools’ proxy statement for its 2026 annual meeting of stockholders (including under the headings “Management and Corporate Governance,” “Executive Officer and Director Compensation,” “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters,” “Executive Compensation” and “Certain Relationships and Related Transactions, and Director Independence”), its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, subsequent Quarterly Reports on Form 10-Q and Standard BioTools’ other filings with the SEC. Information regarding Treeline’s directors and executive officers who may be deemed participants in the solicitation is contained in the registration statement on Form S-4 filed by Standard BioTools. These documents are or will be available free of charge at the SEC’s website at www.sec.gov or by going to Standard BioTools’ Investor Relations website at http://investors.standardbio.com or contacting Standard BioTools’ Investor Relations department at [email protected].
CHICAGO--(BUSINESS WIRE)---- $ILMN #AI--Fishbone Advisors, a capital markets intelligence firm, today released a new report showing that healthcare's AI narrative has a credibility problem with institutional investors. In every healthcare subsector, roughly half to two-thirds of investors (48% to 67%) agree that management overemphasizes AI relative to its actual financial contribution, the most consistent finding in “Hallucinating Value: Healthcare's AI Narrative.” The findings come from the Fishbone Health.
Amova Asset Management Americas Inc. trimmed its position in Illumina, Inc. (NASDAQ:ILMN – Free Report) by 18.6% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 721,532 shares of the life sciences company’s stock after selling 165,333 shares during the period. Illumina comprises 1.3% of Amova Asset Management Americas Inc.’s portfolio, making the stock its 25th biggest holding. Amova Asset Management Americas Inc. owned about 0.48% of Illumina worth $88,864,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Elyxium Wealth LLC bought a new position in Illumina in the fourth quarter worth approximately $25,000. Creative Capital Management Investments LLC grew its position in shares of Illumina by 160.0% during the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after acquiring an additional 120 shares during the period. TD Waterhouse Canada Inc. bought a new stake in shares of Illumina during the 4th quarter valued at $26,000. Laurel Wealth Advisors LLC purchased a new stake in shares of Illumina in the 4th quarter worth $26,000. Finally, Activest Wealth Management increased its stake in shares of Illumina by 671.9% in the 4th quarter. Activest Wealth Management now owns 247 shares of the life sciences company’s stock worth $32,000 after purchasing an additional 215 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.
Illumina Stock Down 1.1% NASDAQ ILMN opened at $184.68 on Tuesday. Illumina, Inc. has a 12 month low of $88.00 and a 12 month high of $196.66. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. The stock has a market cap of $27.94 billion, a PE ratio of 33.58, a P/E/G ratio of 3.49 and a beta of 1.47. The stock’s 50 day moving average is $167.28 and its 200 day moving average is $143.77.
Illumina (NASDAQ:ILMN – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The business had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same period last year, the firm posted $0.97 EPS. The company’s revenue was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Research analysts predict that Illumina, Inc. will post 5.22 EPS for the current fiscal year.
Insider Activity at Illumina In other Illumina news, CAO Scott D. Ericksen sold 500 shares of the business’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $160.00, for a total value of $80,000.00. Following the sale, the chief accounting officer owned 14,446 shares in the company, valued at $2,311,360. The trade was a 3.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of the stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $162.59, for a total transaction of $127,307.97. Following the transaction, the senior vice president directly owned 21,259 shares of the company’s stock, valued at $3,456,500.81. This trade represents a 3.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 1,003,769 shares of company stock valued at $155,710,908. 2.90% of the stock is currently owned by insiders.
Analyst Upgrades and Downgrades A number of brokerages recently commented on ILMN. Wall Street Zen cut Illumina from a “buy” rating to a “hold” rating in a report on Saturday. Citigroup upped their price target on Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a research report on Monday, May 4th. Barclays raised their price objective on Illumina from $122.00 to $145.00 and gave the stock an “underweight” rating in a research note on Wednesday, June 24th. Piper Sandler lifted their price objective on Illumina from $170.00 to $200.00 and gave the company an “overweight” rating in a research report on Wednesday, July 1st. Finally, TD Cowen reiterated a “hold” rating on shares of Illumina in a research note on Wednesday, July 15th. Nine equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Illumina has an average rating of “Hold” and a consensus target price of $156.88.
Get Our Latest Analysis on Illumina
Illumina Company Profile (Free Report)
Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.
Featured Articles Five stocks we like better than Illumina The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINED.A. Davidson & CO. Boosts Stock Position in Expand Energy Corporation $EXE
NEXT HEADLINE »Andar Capital Management HK Ltd Sells 733 Shares of Lumentum Holdings Inc. $LITE
Partners will use unprecedented data scale to advance more precise medicines to approval
, /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that the Billion Cell Atlas alliance has added three new member companies, including AI-native drug developer Formation Bio. As leaders in AI-driven drug discovery, design, and development, alliance members will use the unprecedented scale of Illumina's genome-wide perturbation data as infrastructure for the next generation of therapeutics.
Partners will use unprecedented data scale to advance more precise medicines to approval. "We are building the cell atlas to address key bottlenecks across the drug discovery and development continuum," said Rami Mehio, senior vice president and general manager of BioInsight at Illumina. "We are creating the foundational framework to train virtual cell models and solve some of the most fundamental challenges in biology. Together, partners using this unique dataset can have a significant impact in de-risking and accelerating the journey from biological insights to approved drugs."
Introduced in January 2026 with founding participants AstraZeneca, Merck, and Eli Lilly and Company, the Atlas enables users to discover and validate novel targets, characterize drug and disease mechanisms of action, and explore potential new indications. Over 350 million cells have been sequenced to date, generating upwards of six petabytes of genomic data. The scale and diversity of the Atlas across hundreds of disease-relevant and healthy cell types can reveal how diseases originate and develop, as well as how we may be able to reverse their progression.
"Formation Bio's model is to identify and acquire promising medicines already close to or in the clinic, then use AI and technology to develop them faster and more efficiently. A core part of that model is making better asset-selection and indication decisions, especially for first-in-class programs where the evidence is often fragmented," said Benjamine Liu, CEO and co-founder of Formation Bio. "We are excited to leverage the Illumina Billion Cell Atlas to credential therapeutic-area hypotheses and target-indication pairs against a new layer of cell-specific causal biology. Combined with genetics, human biology, translational evidence, and clinical data, these insights can help us choose the right assets, indications, patients, and trial designs—and ultimately increase the probability that important new medicines reach patients."
Transforming drug discovery and development requires biological understanding at scale
For Formation Bio, the Atlas can provide insight into why a drug might work or fail in a specific patient population. Single-cell perturbation data at scale will enable researchers to build more precise models of how candidate drugs interact with disease biology, improving their ability to identify which patient subgroups are most likely to respond and inform clinical trial design. The Atlas will also strengthen one of the most consequential decisions in drug development: choosing which assets to advance and in which indications.
This is particularly important for first-in-class medicines, where the target biology may be compelling but clinical precedent is limited. By integrating cell-state-specific perturbation data with genetic, human, translational, and clinical evidence, Formation Bio can more rigorously credential target-indication pairs, identify the disease contexts and patient populations most likely to respond, and prioritize programs with the strongest probability of clinical success.
"The next frontier of AI in biology hinges on the creation of foundational training datasets," said Kyle Farh, vice president of Artificial Intelligence at Illumina. "Up until now, most single cell data has been observational. We aim to change that, and in the process, reimagine what is possible in biology."
About the Illumina Billion Cell Atlas
The Illumina Billion Cell Atlas — the world's largest genome-wide genetic perturbation dataset — is capturing how one billion individual cells respond to genetic changes via CRISPR across more than 200 disease-relevant cell lines. The program launched in January 2026, and members include AstraZeneca, Eli Lilly and Company, Formation Bio, Merck, and two additional AI-driven drug discovery partners. It will be the most comprehensive map of human disease biology upon completion. To learn more about the Illumina Billion Cell Atlas and other multiomics initiatives, visit this link.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Illumina (ILMN - Free Report) San Diego, CA.-based Illumina Inc. provides sequencing and array-based solutions for genetic and genomic analysis. The products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. Its customers include leading genomic research centers, academic institutions, government laboratories, hospitals as well as pharmaceutical, biotechnology, commercial molecular diagnostic and consumer genomics companies.
ILMN is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.
Additionally, the company could be a top pick for growth investors. ILMN has a Growth Style Score of B, forecasting year-over-year earnings growth of 7.2% for the current fiscal year.
Two analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.02 to $5.19 per share. ILMN also boasts an average earnings surprise of +12.2%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, ILMN should be on investors' short list.
, /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the second quarter 2026 following the close of market on Thursday, July 30, 2026.
On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.
Conference Call Details
The conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, July 30, 2026. Interested parties may access the live webcast via the Investor Info section of Illumina's website or directly through the following link - https://illumina-earnings-call-q2-2026.open-exchange.net/. To ensure timely connection, please join at least ten minutes before the scheduled start of the call.
A replay of the conference call will be posted on Illumina's website after the event and will be available for at least 30 days following.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with us on X (Twitter), Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.
While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.
Below, we take a look at Illumina (ILMN - Free Report) , which currently has a Momentum Style Score of B. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions.
It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Illumina currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of "A or B" outperform the market over the following one-month period.
You can see the current list of Zacks #1 Rank Stocks here >>>
Set to Beat the Market?Let's discuss some of the components of the Momentum Style Score for ILMN that show why this genetic testing tools company shows promise as a solid momentum pick.
A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It's also helpful to compare a security to its industry; this can show investors the best companies in a particular area.
For ILMN, shares are up 6.87% over the past week while the Zacks Medical - Biomedical and Genetics industry is up 2.25% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 15.6% compares favorably with the industry's 10% performance as well.
While any stock can see a spike in price, it takes a real winner to consistently outperform the market. Over the past quarter, shares of Illumina have risen 42%, and are up 92.74% in the last year. In comparison, the S&P 500 has only moved 10.61% and 21.48%, respectively.
Investors should also take note of ILMN's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. Right now ILMN is averaging 1,920,957 shares for the last 20 days..
Earnings OutlookThe Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with ILMN.
Over the past two months, 2 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost ILMN's consensus estimate, increasing from $5.17 to $5.19 in the past 60 days. Looking at the next fiscal year, 2 estimates have moved upwards while there have been no downward revisions in the same time period.
Bottom LineTaking into account all of these elements, it should come as no surprise that ILMN is a #2 (Buy) stock with a Momentum Score of B. If you've been searching for a fresh pick that's set to rise in the near-term, make sure to keep Illumina on your short list.
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +23.94% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Illumina (ILMN - Free Report) San Diego, CA.-based Illumina Inc. provides sequencing and array-based solutions for genetic and genomic analysis. The products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. Its customers include leading genomic research centers, academic institutions, government laboratories, hospitals as well as pharmaceutical, biotechnology, commercial molecular diagnostic and consumer genomics companies.
ILMN is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.
Momentum investors should take note of this Medical stock. ILMN has a Momentum Style Score of B, and shares are up 15.6% over the past four weeks.
Two analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.02 to $5.19 per share. ILMN also boasts an average earnings surprise of +12.2%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, ILMN should be on investors' short list.
SummaryIllumina commands 90%+ market share in genomics sequencing, powering a $30B+ TAM growing at double digits with a robust razor-and-blades model.Post-GRAIL, management’s renewed focus on core sequencing, cost control, and capital return is driving revenue recovery, margin expansion, and free cash flow.NovaSeq X placements and consumables pull-through are key near-term catalysts; 65%+ of consumables revenue is clinical, supporting high margins and recurring cash flows.ILMN trades at a reasonable P/E versus peers, offering a rare blend of secular growth and defensive healthcare positioning, with credible execution and risk controls in place.Summary Illumina (ILMN) is at the center of a genomics revolution that is stealthily going mainstream. Machines like the NovaSeq X are helping revenue recover and margins expand, and the management team has smartly refocused the post-GRAIL calculated reset on what
457 Followers
Analyst’s Disclosure: I/we have a beneficial long position in the shares of ILMN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Key Takeaways Illumina's 2026 stock rally reflects strong execution and first-quarter results above guidance.ILMN saw 20% clinical sequencing consumables demand growth outside China for a second straight quarter.Illumina's NovaSeq X placements topped 80 units as adoption and platform transition continued. Illumina (ILMN - Free Report) has delivered an impressive performance in 2026, with its shares rising 43.7% year to date. The stock has significantly outpaced the industry’s 7.5% gain and the S&P 500 composite’s 10% rise.
Carrying a Zacks Rank #2 (Buy) at present, the renowned genomics company continues to execute on its strategy to drive durable growth and higher profitability. Growing sequencing intensity across the clinical end-markets continues to support Illumina’s growth. Balance sheet strength remains another key positive for the company.
San Diego, CA.-based Illumina Inc. provides sequencing and array-based solutions for genetic and genomic analysis. The products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. Its customers include leading genomic research centers, academic institutions, government laboratories, hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic and consumer genomics companies. The company’s sequencing technology, sequencing by synthesis (SBS), is widely adopted worldwide and supports both single-read and paired-end libraries.
Key Drivers Behind ILMN's Price RallySince spinning off GRAIL in June 2024, Illumina has continued to center its strategy on the core sequencing franchise while scaling into adjacent multiomics and data offerings. The company is targeting a return to durable growth and higher profitability, with goals of high-single-digit revenue growth by 2027 and annual earnings per share (EPS) growth in the double-digits to teens. The strategy appears to be gaining traction, with first-quarter 2026 revenues, margins and non-GAAP EPS all exceeding management’s guidance.
Image Source: Zacks Investment Research
Broader adoption of NGS-based testing remains a key growth driver for Illumina. Clinical end-markets generated the majority of sequencing consumables revenues in first-quarter 2026, supported by the continued adoption of sequencing-based diagnostics and the growing use of sequencing-intensive tests, including comprehensive genomic profiling and whole genome sequencing, as drivers of higher sequencing intensity. Excluding China, clinical sequencing consumables demand increased 20% for the second straight quarter.
NovaSeq X placements in the quarter exceeded 80 units, around 20 more than a year ago and above the company’s targeted quarterly range. Transition progress also continued, with approximately 82% of volumes and 55% of revenues migrated to the platform, while roughly 90% of research and applied volume now runs on NovaSeq X. Management continues to plan for average quarterly NovaSeq X placements of 50 to 60 through 2026 while investing to scale supply given the current pipeline. Meanwhile, Illumina continues to expand its oncology menu as customers scale sequencing in clinical decision-making and in new trials that require larger information sets.
ILMN’s balance sheet also remains in solid shape. The company exited the first quarter of 2026 with cash and cash equivalents of $1.09 billion compared with $1.42 billion at the end of fourth-quarter 2025. Current debt was $499 million, unchanged sequentially, while long-term debt remained $1.49 billion.
Key Risks for IlluminaThe company continues to operate in a higher-cost environment shaped by tariffs and supply-chain inflation, which can affect both demand and margins. It also faces constrained demand in Greater China amid ongoing regulatory and geopolitical uncertainty, keeping the region out of step with the rest of the business.
A Look at ILMN’s EstimatesThe Zacks Consensus Estimate projects Illumina's 2026 and 2027 earnings per share (EPS) at $5.19 and $5.86, reflecting year-over-year growth of 7.2% and 12.9%, respectively. The consensus estimate for 2026 EPS has moved 0.4% higher over the past 30 days.
Revenues are expected to increase 5.1% to $4.56 billion in 2026, followed by another 6.2% increase to $4.85 billion in 2027.
Key PicksSome other top-ranked stocks in the broader medical space are IDEXX Laboratories (IDXX - Free Report) , Align Technology (ALGN - Free Report) and Integra LifeSciences (IART - Free Report) .
IDEXX Laboratories has an earnings yield of 2.6% compared to the industry’s negative 3% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 26.3%. IDXX shares have rallied 2.7% against the industry’s 8.2% decline over the past year.
IDXX carries a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Align Technology, carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 10.3% compared with the industry’s 5.5% growth. Shares of the company have dipped 14.5% against the industry’s 10.5% growth. ALGN’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 7.8%.
Integra LifeSciences, carrying a Zacks Rank #2, has an earnings yield of 13.7% against the industry’s negative 3% yield. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 16.7%. IART shares have rallied 31.4% against the industry’s 8.2% decline over the past year.
New leaders bring extensive leadership experience across life sciences, diagnostics, and medical technology
, /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the appointment of Mike Sullivan as Chief Commercial Officer, effective July 20, 2026, and Julie Coletti as Chief Legal Officer, effective August 3, 2026.
The appointments add experienced leaders to Illumina's Executive Leadership Team as the company continues advancing its strategy, serving customers, driving growth, and delivering on its mission to improve human health around the world.
"We are excited to welcome Mike and Julie to Illumina," said Jacob Thaysen, chief executive officer of Illumina. "Mike brings deep commercial expertise, a customer-first mindset, and significant experience scaling global organizations, while Julie is a highly accomplished legal and business leader with deep experience across the life sciences and medical technology sectors. I look forward to working closely with both of them as we continue helping customers unlock new insights across genomics, multiomics, and human health."
Sullivan will be responsible for leading Illumina's global commercial organization. He brings more than 30 years of commercial leadership experience across diagnostics, precision medicine, healthcare, and life sciences, with a proven track record of driving growth, expanding customer adoption, and leading high-performing global teams.
Most recently, Sullivan served as Chief Commercial Officer at Caris Life Sciences, where he led the company's global commercial operations across oncology diagnostics and precision medicine. Prior to Caris, he held senior commercial leadership roles at Roche Diagnostics, Ortho Clinical Diagnostics, IDEXX Laboratories, and Abbott Diagnostics.
As Chief Legal Officer, Coletti will lead Illumina's global legal, regulatory, and government affairs teams and serve as corporate secretary to the Illumina Board of Directors. Coletti joins with extensive legal, regulatory, and governance expertise across the life sciences and medical technology sectors.
Previously, Coletti served as Chief Legal and Regulatory Officer at Align Technology. Prior to that, she held senior legal leadership positions at Danaher Corporation and Bayer HealthCare, advising executive leaders and boards of directors on a broad range of complex issues, including compliance matters, intellectual property, competition, governance, and public policy. She also serves as a director for Fortis Life Sciences, a provider of solutions to life science and diagnostic companies.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Key Takeaways Healthcare robotics is expanding into surgery, diagnostics, lab automation and orthopedics. Robotics ETFs are adding more healthcare automation exposure alongside industrial robotics. ETFs like ROBO offer exposure to healthcare automation innovators alongside robotics and AI companies. While electric vehicles and tech giants like Tesla (TSLA - Free Report) and Alphabet (GOOGL - Free Report) dominate headlines in the robotics space, a powerful transformation has reached an inflection point in healthcare. Over the past decade, robotics in medicine has moved from early adoption to mainstream scale.
This acceleration has been driven by an aging global population, a persistent shortage of skilled surgeons and clinical staff, and the increasing push for minimally invasive procedures that offer faster recovery times and better patient outcomes. What was once dominated by the use of robots in a handful of guided surgeries has now expanded into varied branches ranging from orthopedics and pharmacy automation to artificial intelligence (AI)-driven diagnostics.
For investors looking to capitalize on this clinical migration, the challenge lies in differentiation. While standard healthcare funds offer stable dividends, they often dilute the tech-driven upside of advanced engineering.
Broad robotics exchange-traded funds (ETFs), which have historically prioritized factory automation, material handling, and semiconductor equipment suppliers, have expanded their allocation to med-tech innovators like Intuitive Surgical (ISRG - Free Report) in the recent past.
Evaluating the true potential of these robotics ETFs requires a ground-up look at the dominant healthcare stocks leading the charge and the clinical market dynamics driving their bottom lines.
Pioneering Stocks in Healthcare RoboticsSeveral key healthcare stocks demonstrate the broad range of robotics applications across the medical field, a few of which are discussed below.
• Intuitive Surgical: As the pioneer in robotic-assisted surgery, its da Vinci system is a household name, allowing for complex procedures through small incisions. The company continues to show strong performance for this product, with Da Vinci procedures having risen approximately 16% year over year in the first quarter of 2026.
ISRG grew its da Vinci surgical system installed base to 11,395 systems as of March 31, 2026, reflecting an increase of 12%. The new da Vinci 5 platform is driving higher utilization, and its data-rich ecosystem is creating a long-term competitive advantage in AI.
• Illumina (ILMN - Free Report) : While best known for its gene-sequencing technology, Illumina is a prime example of robotics in lab automation. The company developed robotic systems like the Infinium Automated Pipetting System, which automates highly labor-intensive sample preparation workflows, as well as Digital Microfluidics, which is a droplet-based automation technology that moves, merges, and mixes liquid droplets using electrical signals. This minimizes human error and dramatically reduces processing time, which are critical for large-scale genomic studies and clinical diagnostics.
• Stryker (SYK - Free Report) : A major player in medical devices, Stryker is a leader in orthopedic robotics. Its Mako system is used for robotic-arm assisted total knee, partial knee, and total hip replacements, offering surgeons enhanced precision and control. This technology has benefited the company's financial performance.
From surgical precision to laboratory efficiency, these examples illustrate how robotics is becoming integral to modern healthcare delivery across multiple specialties.
Industry Outlook and the Role of ETFsAs technology advances, we are moving closer to AI-enhanced surgical systems that improve decision-making, micro-robotic devices capable of navigating the human body for targeted therapy, and autonomous diagnostic tools that assist in early disease detection.
Against this backdrop, the outlook for healthcare robotics is exceptionally bright. According to a report published by Johns Hopkins University in May 2025, the global healthcare robotics market is expected to increase from approximately $14.9 billion in 2023 to $57.0 billion by 2032.
While picking a single winner in this rapidly growing $57 billion market can be challenging, investing in a specialized robotics ETF provides a more balanced entry point. Rather than relying on a single clinical breakthrough, these funds grant investors exposure to the entire robotics value chain.
This diversified approach can potentially boost profits by capturing growth across industrial automation, logistics, and other sectors, while mitigating the risk associated with any single company or sub-sector.
Robotics ETFs to ConsiderFor investors looking to tap into the robotics industry’s pioneering growth prospects, the following ETFs stand out:
Global X Robotics & Artificial Intelligence ETF (BOTZ - Free Report)
This fund, with net assets worth $3.43 billion, offers exposure to 62 companies that potentially stand to benefit from increased adoption and utilization of robotics and AI, including those involved in industrial robotics and automation, non-industrial robots, and autonomous vehicles. Keyence Corp holds the first spot in this fund, with 9.69% weightage, while ISRG holds the fifth position with 6.72% weightage.
BOTZ has rallied 13.1% over the past year. The fund charges 68 basis points (bps) as fees and traded at a good volume of 1.33 million shares in the last trading session.
ROBO Global Robotics and Automation Index ETF (ROBO - Free Report)
This fund, with net assets worth $2.09 billion, offers exposure to 79 companies that are driving transformative innovations in robotics, automation, and artificial intelligence (RAAI), including companies that create technology to enable truly intelligent systems that can sense, process, and act, and companies that apply those technologies to deliver RAAI-enabled products, including robots, to businesses and consumers. Harmonic Drive Systems holds the first spot in this fund, with 1.92% weightage, while ISRG holds the fourth position with 1.77% weightage. ILMN holds the sixth spot in this fund, with 1.69% weightage.
ROBO has surged 36.2% over the past year. The fund charges 95 bps as fees and traded at a volume of 0.29 million shares in the last trading session.
First Trust NASDAQ Artificial Intelligence and Robotics ETF (ROBT - Free Report)
This fund, with net assets worth $728.2 million, offers exposure to 114 companies engaged in AI, robotics and automation. Palo Alto Networks holds the first spot in this fund, with 1.87% weightage, while ILMN holds the fourth position with 1.75% weightage.
ROBT has risen 15% over the past year. The fund charges 65 bps as fees and traded at a volume of 0.03 million shares in the last trading session.
Shares of Illumina (ILMN - Free Report) have been strong performers lately, with the stock up 19.8% over the past month. The stock hit a new 52-week high of $196.66 in the previous session. Illumina has gained 46.2% since the start of the year compared to the 2.8% gain for the Zacks Medical sector and the 7.4% return for the Zacks Medical - Biomedical and Genetics industry.
What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on April 30, 2026, Illumina reported EPS of $1.15 versus consensus estimate of $1.05.
For the current fiscal year, Illumina is expected to post earnings of $5.19 per share on $4.56 in revenues. This represents a 7.23% change in EPS on a 5.09% change in revenues. For the next fiscal year, the company is expected to earn $5.86 per share on $4.85 in revenues. This represents a year-over-year change of 12.91% and 6.2%, respectively.
Valuation MetricsWhile Illumina has moved to its 52-week high over the past few weeks, investors need to be asking, what is next for the company? A key aspect of this question is taking a look at valuation metrics in order to determine if the company has run ahead of itself.
On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). The individual style scores for Value, Growth, Momentum and the combined VGM Score run from A through F. Investors should consider the style scores a valuable tool that can help you to pick the most appropriate Zacks Rank stocks based on their individual investment style.
Illumina has a Value Score of C. The stock's Growth and Momentum Scores are B and D, respectively, giving the company a VGM Score of B.
In terms of its value breakdown, the stock currently trades at 36.9X current fiscal year EPS estimates, which is a premium to the peer industry average of 21.7X. On a trailing cash flow basis, the stock currently trades at 28.6X versus its peer group's average of 15.1X. Additionally, the stock has a PEG ratio of 3.6. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.
Zacks RankWe also need to consider the stock's Zacks Rank, as this supersedes any trend on the style score front. Fortunately, Illumina currently has a Zacks Rank of #2 (Buy) thanks to a solid earnings estimate revision trend.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Illumina meets the list of requirements. Thus, it seems as though Illumina shares could have a bit more room to run in the near term.
How Does ILMN Stack Up to the Competition?Shares of ILMN have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is Kiniksa Pharmaceuticals International, plc (KNSA - Free Report) . KNSA has a Zacks Rank of #1 (Strong Buy) and a Value Score of D, a Growth Score of A, and a Momentum Score of A.
Earnings were strong last quarter. Kiniksa Pharmaceuticals International, plc beat our consensus estimate by 50.00%, and for the current fiscal year, KNSA is expected to post earnings of $1.25 per share on revenue of $938.98 million.
Shares of Kiniksa Pharmaceuticals International, plc have gained 38.2% over the past month, and currently trade at a forward P/E of 53.69X and a P/CF of 84.77X.
The Medical - Biomedical and Genetics industry is in the top 45% of all the industries we have in our universe, so it looks like there are some nice tailwinds for ILMN and KNSA, even beyond their own solid fundamental situation.
Key Takeaways ILMN is focused on core sequencing, multiomics, and software after the GRAIL spin-off.ILMN raised 2026 guidance as Q1 revenues, margins, EPS and NovaSeq X placements topped expectations.ILMN faces China weakness, tariffs and higher input costs that may pressure growth and margins. Illumina Inc. (ILMN - Free Report) is well-poised to grow in the coming quarters owing to its strategic execution against growing the core sequencing business, expanding multiomics and developing services, data and software capabilities. Ongoing momentum in clinical end markets is boosting sequencing consumables demand. Higher-than-expected NovaSeq X placements and continued transition to the platform further strengthen the outlook. Yet, China remains a drag on Illumina’s growth, while input-cost volatility can limit incremental margin upside over the next several quarters.
Over the past year, this Zacks Rank #3 (Hold) stock has surged 87%, well ahead of the industry’s 23.8% growth and the S&P 500 composite’s rise of 22.8%.
The renowned biotechnology company has a market capitalization of $27.82 billion. ILMN’s earnings yield of 2.8% is well ahead of the industry’s -14.9% yield. In the trailing four quarters, it surpassed estimates on all occasions, delivering an average surprise of 12.2%.
Let’s delve deeper.
Tailwinds Behind ILMN StockSharpened Focus on Core Genomics: Following the spin-off of GRAIL in June 2024, Illumina has continued to center its strategy on the core sequencing franchise while scaling into adjacent multiomics and data offerings. The company remains focused on returning to durable growth and higher profitability, aiming for high-single-digit revenue growth by 2027, along with double-digits to teens annual earnings per share (EPS) growth, anchored by its roadmap of growing the core sequencing business, expanding multiomics and building services, data and software capabilities.
Image Source: Zacks Investment Research
First-quarter 2026 results reinforced that direction, with revenues, margins and non-GAAP EPS exceeding guidance. Management also raised full-year 2026 guidance, now expecting revenues in the range of $4.52-$4.62 billion and non-GAAP diluted EPS in the range of $5.15-$5.30, alongside a modest step-up in the non-GAAP operating margin outlook between 23.4% and 23.6%.
NovaSeq X Placements and Transition Progress: Illumina’s core sequencing business remains anchored by NovaSeq X. First-quarter 2026 placements exceeded 80 units, around 20 more than the prior-year quarter and above the company’s targeted quarterly range. Demand remains strong for the platform, especially with clinical. Management noted supply constraints in meeting first-quarter placement demand while exiting the quarter with a backlog that supported a higher full-year instrument outlook.
Transition progress also continued, with approximately 82% of volumes and 55% of revenues transitioned to NovaSeq X in the first quarter, and roughly 90% of research and applied volume now on the platform. Management continues to plan for average quarterly NovaSeq X placements of 50 to 60 through 2026 while investing to scale supply given the current pipeline.
Clinical Demand Remains the Key Driver: Illumina continues to benefit from the broader adoption of NGS-based testing, with clinical markets now representing the majority of sequencing consumables revenues in first-quarter 2026. Management cited continued adoption of sequencing-based diagnostics and growing use of sequencing-intensive tests, including comprehensive genomic profiling and whole genome sequencing, as drivers of higher sequencing intensity.
Clinical sequencing consumables demand grew 20%, excluding China, for the second consecutive quarter, and management continues to expect most clinical volumes to transition to NovaSeq X by the end of 2026. Over time, the mix shift toward higher-throughput clinical workflows should remain supportive for consumables growth even as research demand stays uneven.
What Ails ILMN?Setbacks in China Market: Illumina continues to face constrained demand in Greater China amid ongoing regulatory and geopolitical uncertainty, keeping the region out of step with the rest of the business. In first-quarter 2026, Greater China revenues were $52 million, down 27.8% year over year. With Illumina still operating under uncertainty tied to its status with Chinese authorities and the resulting friction on commercial activity, visibility on a sustained recovery in China remains limited and can weigh on overall growth and operating leverage.
Macroeconomic Pressures Remain a Concern: Illumina continues to operate in a higher-cost environment shaped by tariffs and supply-chain inflation, which can affect both demand and margins. In the first quarter of 2026, tariffs were a partial offset to underlying cost efficiencies and revenue leverage.
Second-quarter guidance calls for an operating margin of around 22%, reflecting a higher instrument mix, near-term inflationary impacts tied to freight and higher electronic component costs, and incremental costs from a full quarter of SomaLogic. Management expects mitigation actions to offset these cost items over the balance of the year, but ongoing volatility in trade policy and input costs can still create uneven quarterly performance and limit visibility for customers facing tighter budgets.
ILMN Stock Estimate TrendThe Zacks Consensus Estimate for ILMN’s 2026 EPS has increased 0.4% to $5.19 in the past 30 days.
The Zacks Consensus Estimate for the company’s 2026 revenues is pegged at $4.56 billion. This suggests a 5.1% rise from the year-ago reported number.
Key PicksSome better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Align Technology (ALGN - Free Report) and Integra LifeSciences (IART - Free Report) .
Globus Medical has an earnings yield of 6.2% compared to the industry’s negative 3% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 26.3%. GMED shares have rallied 35.4% against the industry’s 10.6% decline over the past year.
GMED carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Align Technology, sporting a Zacks Rank #1, has an estimated long-term earnings growth rate of 10.3% compared with the industry’s 5.5% growth. Shares of the company have dipped 6.3% against the industry’s 9.6% growth. ALGN’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 7.8%.
Integra LifeSciences, carrying a Zacks Rank #2, has an earnings yield of 13.7% against the industry’s negative 3% yield. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 16.7%. IART shares have rallied 33.8% against the industry’s 10.5% decline over the past year.
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Astrazeneca (AZN - Free Report) and Illumina (ILMN - Free Report) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.
Astrazeneca and Illumina are sporting Zacks Ranks of #2 (Buy) and #3 (Hold), respectively, right now. This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that AZN is likely seeing its earnings outlook improve to a greater extent. But this is just one piece of the puzzle for value investors.
Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.
AZN currently has a forward P/E ratio of 18.43, while ILMN has a forward P/E of 33.85. We also note that AZN has a PEG ratio of 1.50. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. ILMN currently has a PEG ratio of 3.30.
Another notable valuation metric for AZN is its P/B ratio of 6.21. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. For comparison, ILMN has a P/B of 9.94.
These are just a few of the metrics contributing to AZN's Value grade of B and ILMN's Value grade of C.
AZN is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. And, based on the above valuation metrics, we feel that AZN is likely the superior value option right now.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Illumina (ILMN - Free Report) San Diego, CA.-based Illumina Inc. provides sequencing and array-based solutions for genetic and genomic analysis. The products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. Its customers include leading genomic research centers, academic institutions, government laboratories, hospitals as well as pharmaceutical, biotechnology, commercial molecular diagnostic and consumer genomics companies.
ILMN is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Additionally, the company could be a top pick for growth investors. ILMN has a Growth Style Score of B, forecasting year-over-year earnings growth of 7.2% for the current fiscal year.
Six analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.08 to $5.19 per share. ILMN also boasts an average earnings surprise of +12.2%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, ILMN should be on investors' short list.
A 3D printed DNA Helix model and word "DNA" are seen in this illustration taken February 4, 2026. REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights, opens new tab
CompaniesLONDON/ZURICH, June 29 (Reuters) - Swiss pharma and diagnostics giant Roche on Monday launched its long-awaited Axelios gene sequencer, in a bid to challenge U.S. firm Illumina's (ILMN.O), opens new tab leadership in next-generation sequencing.
Roche's launch is limited to academic and research-focused facilities and comes more than a decade after the group's failed $6.8 billion hostile bid to acquire Illumina.
Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.
The Axelios platform is designed to rapidly read and analyse DNA at scale, supporting applications from disease research to drug development.
Analysts say Roche's entry is likely to be a gradual push for market share rather than a rapid disruption of the sector, which is valued at about $7.3 billion. Illumina remains the clear leader, with estimates putting its share of NGS systems at around 70%.
Roche said it aims to place about 100 machines in the first year, a target that will lay the foundation for a future "blockbuster" franchise generating over 1 billion Swiss francs ($1.1 billion) in annual sales over the long term.
The company has partnered with 10x Genomics (TXG.O), opens new tab and Google (GOOGL.O), opens new tab DeepVariant for data analysis, backed by early platform validation from Broad Clinical Labs and the Hartwig Medical Foundation to ease adoption.
Roche said it has already begun commercial shipments and booked pre-orders. The launch is focused on U.S., UK, Germany, France, among others and Roche expects to quickly expand into other geographies.
Reporting by Bhanvi Satija in London and Marleen Kaesebier in Zurich, Editing by Louise Heavens
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Bhanvi is a London-based reporter covering European pharmaceutical companies and the healthcare industry. She previously covered U.S. health and pharma firms, with a focus on the new weight loss drugs that are transforming the obesity treatment space. Her coverage includes a trend piece on the underuse of their weight-loss drugs among men, increased interest in therapies being developed for preservation of lean mass, and a scoop on gene therapy maker Sarepta defying an FDA order to stop shipping its muscular dystrophy treatment.
Marleen is a company correspondent based in Zurich where she covers the likes of Swiss pharma and insurance. Previously, she wrote about Swiss and German markets as a news reporter and graduated from the Columbia Journalism School.
Eli Lilly and Company's Chief Scientific and Product Officer brings pharmaceutical R&D and scientific leadership perspective to Illumina's Board
, /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the appointment of Daniel M. Skovronsky, MD, PhD, to its Board of Directors, effective June 16, 2026. Dr. Skovronsky brings extensive experience in drug discovery, clinical development and translational medicine, which are areas directly relevant to Illumina's work advancing genomics and multiomics platforms.
Illumina appointed Daniel M. Skovronsky, MD, PhD, to its Board of Directors. "Dan brings a rare combination of scientific expertise, innovation leadership, and healthcare impact," said Jacob Thaysen, chief executive officer of Illumina. "His experience building and advancing large research portfolios gives our Board a perspective that can help strengthen Illumina's ability to drive innovation across genomics, multiomics, and precision medicine."
Dr. Skovronsky currently serves as Chief Scientific and Product Officer of Eli Lilly and Company and President of Lilly Research Laboratories, where he leads Lilly's global research and development organization and oversees commercial products across Lilly Cardiometabolic Health, Lilly Immunology, and Lilly Neuroscience.
He joined Lilly in 2010, following the acquisition of Avid Radiopharmaceuticals, a company he founded in 2004 and led as Chief Executive Officer. Since joining Lilly, he has held roles of increasing responsibility across the organization.
He previously served on the Board of Directors of Myriad Genetics, Inc.
Dr. Skovronsky received a Bachelor of Science in molecular biophysics and biochemistry from Yale University and earned both his MD and PhD from the University of Pennsylvania. He completed residency training in pathology and fellowship training in neuropathology at the Hospital of the University of Pennsylvania.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +24% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Illumina (ILMN - Free Report) San Diego, CA.-based Illumina Inc. provides sequencing and array-based solutions for genetic and genomic analysis. The products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. Its customers include leading genomic research centers, academic institutions, government laboratories, hospitals as well as pharmaceutical, biotechnology, commercial molecular diagnostic and consumer genomics companies.
ILMN is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
Momentum investors should take note of this Medical stock. ILMN has a Momentum Style Score of A, and shares are up 16% over the past four weeks.
For fiscal 2026, five analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.07 to $5.19 per share. ILMN boasts an average earnings surprise of +12.2%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, ILMN should be on investors' short list.
Key Takeaways ILMN Q1 EPS of $1.15 beat estimates by 9.7% and rose 18.6% year over year. Illumina revenues hit $1.09B, up 4.8%, with both segments posting growth.ILMN raised 2026 guidance, projecting up to $4.62B revenues and up to $5.30 EPS. Illumina Inc. (ILMN - Free Report) reported first-quarter 2026 adjusted earnings per share (EPS) of $1.15, which topped the Zacks Consensus Estimate by 9.7%. The figure was up 18.6% on a year-over-year basis.
Including one-time items, the company’s GAAP EPS was 87 cents compared with 82 cents a year ago.
Illumina’s RevenuesFirst-quarter revenues amounted to $1.09 billion, up 4.8% year over year and up 3.5% on a constant-currency basis. The top line beat the Zacks Consensus Estimate by 1.1%.
Following the earnings announcement, Illumina shares edged up 5.3% yesterday.
Illumina’s Segmental DetailsIllumina generates revenues from two segments – Product, and Services and other.
Product revenues totaled $917 million, up 4.2% year over year. Meanwhile, Services and other revenues amounted to $174 million, up 8.1% year over year.
ILMN’s MarginsThe adjusted gross margin (including amortization of acquired intangible assets) was 66.1%, up 48 basis points (bps) year over year despite a 3.3% rise in the cost of revenues.
Research and development expenses decreased 4.8% year over year to $240 million. SG&A expenses totaled $272 million, up 1.9% from the year-ago level. Adjusted operating margin expanded 340 bps to 19.2%.
Illumina’s Financial UpdateIllumina exited the first quarter of 2026 with cash and cash equivalents of $1.09 billion compared with $1.42 billion at the end of the fourth quarter of 2025.
Cumulative net cash provided by operating activities totaled $289 million compared with $240 million a year ago.
Illumina’s 2026 GuidanceThe company expects total revenues to be in the range of $4.52-$4.62 billion (up from $4.50-$4.60 billion), suggesting growth of 4-6% on a reported basis. The Zacks Consensus Estimate for 2026 revenues is currently pinned at $4.53 billion.
Non-GAAP diluted EPS is projected to be in the range of $5.15-$5.30 (up from $5.05-$5.20) in 2026. The Zacks Consensus Estimate for full-year EPS is currently pegged at $5.12.
Illumina, Inc. Price, Consensus and EPS SurpriseOur Take on ILMNIllumina exited the first quarter of 2026 with better-than-expected results, wherein both earnings and revenues beat estimates. The company delivered a strong 2025 performance, marking a return to growth through disciplined execution.
All the business segments reported growth in the quarter. Given the strong first-quarter performance, Illumina raised its full-year 2026 guidance.
The expansion of both the margin looks encouraging.
ILMN’s Zacks Rank & Key PicksIllumina currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Intuitive Surgical (ISRG - Free Report) and Phibro Animal Health (PAHC - Free Report) .
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2025 adjusted EPS of $1.28, which surpassed the Zacks Consensus Estimate by 20.8%. Revenues of $826.4 million beat the Zacks Consensus Estimate by 4.9%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an earnings yield of 4.7% compared to the industry’s negative yield of 1.4%. The company’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 18.79%.
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, posted a first-quarter 2026 adjusted EPS of $2.50, which exceeded the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion topped the Zacks Consensus Estimate by 6.2%.
ISRG has an earnings yield of 2.1% in contrast to the industry’s negative yield of 0.9%. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.82%.
Phibro Animal Health, carrying a Zacks Rank #2 at present, posted a second-quarter fiscal 2026 adjusted EPS of 87 cents, which outpaced the Zacks Consensus Estimate by 27.01%. Revenues of $373.9 million outperformed the Zacks Consensus Estimate by 4.72%.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.1% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 20.15%.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.93% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Illumina (ILMN - Free Report) San Diego, CA.-based Illumina Inc. provides sequencing and array-based solutions for genetic and genomic analysis. The products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. Its customers include leading genomic research centers, academic institutions, government laboratories, hospitals as well as pharmaceutical, biotechnology, commercial molecular diagnostic and consumer genomics companies.
ILMN is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Additionally, the company could be a top pick for growth investors. ILMN has a Growth Style Score of B, forecasting year-over-year earnings growth of 6.8% for the current fiscal year.
Five analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.01 to $5.17 per share. ILMN also boasts an average earnings surprise of +12.2%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, ILMN should be on investors' short list.
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.93% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Illumina (ILMN - Free Report) San Diego, CA.-based Illumina Inc. provides sequencing and array-based solutions for genetic and genomic analysis. The products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. Its customers include leading genomic research centers, academic institutions, government laboratories, hospitals as well as pharmaceutical, biotechnology, commercial molecular diagnostic and consumer genomics companies.
ILMN is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Momentum investors should take note of this Medical stock. ILMN has a Momentum Style Score of B, and shares are up 10% over the past four weeks.
Five analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.02 to $5.18 per share. ILMN also boasts an average earnings surprise of +12.2%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, ILMN should be on investors' short list.
, /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today published its annual Corporate Responsibility (CR) Report. The report highlights the company's continued progress in expanding equitable access to genomics while delivering measurable impact for patients, communities, and health systems worldwide. It reinforces Illumina's mission-driven culture, sustainability goals, and commitment to genomics for good.
"More than 20 million people are diagnosed with cancer each year. Rare disease patients face years-long diagnostic odysseys to find answers. Health systems are under growing pressure to deliver better outcomes with fewer resources. Genomics can help meet these challenges, but only if it is integrated into real-world settings at scale," said Jacob Thaysen, CEO of Illumina. "The exceptional pace of sequencing on Illumina platforms—over 10 human genomes per minute in 2025—is a strong signal that we are meeting the moment, bringing us closer to a future where personalized medicine improves outcomes for all."
Expanding access to genomics at scale across the globe
Illumina is enabling cost-effective, scalable technologies while championing global policies and initiatives to improve access to genomic medicine. In 2025, Illumina partnered with governments, health systems, and research institutions for population-scale genomics, sovereign data stewardship, and national precision health initiatives that reflect local needs and priorities. The Illumina Corporate Foundation supported efforts around the world to bring next-generation sequencing to patients without access. Illumina contributed to international policy efforts to prioritize rare disease in public health and participated in rare disease hackathons where our new technologies and employee expertise interrogated genomic challenges.
Continuing leadership in sustainability, community engagement
Illumina recognizes that human health and environmental health are fundamentally linked, driving the company to reduce its environmental footprint across business practices while supporting customers' ability to sequence more sustainably. Since 2019, Illumina has reduced product packaging by 87%, surpassing its 2030 target. Over the same period, the company has reduced Scope 1 and 2 greenhouse gas emissions by 74% and achieved 100% renewable electricity for the fourth consecutive year through renewable energy procurement, onsite solar generation, and renewable energy credits (RECs). These efforts earned Illumina recognition as one of TIME's World's Most Sustainable Companies for the second year in a row.
Reflecting the company's commitment to nurturing our people and community, Illumina maintained a zero net pay gap for the seventh consecutive year and surpassed its goal of 100,000 volunteer hours by 2030. Employees have contributed more than 116,000 volunteer hours since 2019, with 50% of employees participating in giving and volunteering opportunities in 2025. Employees routinely bring their passion for education to the classroom, investing in the next generation of scientists. Illumina has reached 2.6 million STEM learners since 2019, including 500,000 in 2025 alone.
As part of the company's dedication to innovation, Illumina continues to expand access to genomic technologies across research, clinical, and population health settings. In 2025, the company launched the Illumina 5-base solution and Illumina Protein Prep, updated the DRAGEN software pipeline, and expanded our oncology portfolio. Illumina also debuted new capabilities such as PromoterAI and strengthened global collaborations with the Alliance for Genomic Discovery, Broad Clinical Labs, and more.
Illumina is pleased to share all of this information and more in its 2025 Corporate Responsibility report, available here.
Forward-Looking Statements
This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, among others, statements regarding Illumina's expectations, plans, and the potential impact of its technologies and initiatives, and are based on Illumina's current expectations, assumptions, and beliefs. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements may be identified by words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "likely," "may," "plan," "potential," "project," "seek," "will," and similar expressions. Factors that could cause actual results to differ materially include, among others: challenges inherent in developing and commercializing new technologies; the rate of adoption of genomic solutions by customers and health systems; regulatory developments and reimbursement considerations; and other factors described in Illumina's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Illumina undertakes no obligation to update any forward-looking statements except as required by law.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Key Takeaways ILMN is advancing its core sequencing strategy with growing clinical demand and NovaSeq X adoption.ILMN clinical consumables demand up 20% ex-China, supported by broader NGS adoption.ILMN faces China weakness and macro pressures despite margin and guidance improvements. Illumina Inc. (ILMN - Free Report) is making strong progress against its long-term strategy and targets, anchored by its roadmap of growing the core sequencing business, expanding multiomics, and building services, data and software capabilities. Continued momentum in clinical end markets supports sequencing consumables growth. The expanding NovaSeq X installed base and utilization are also highly promising. Yet, headwinds from China’s operations and macroeconomic pressures raise concerns for the company.
Over the past year, this Zacks Rank #3 (Hold) stock has surged 68.3%, well ahead of the industry’s16.3% growth and the S&P 500 composite’s rise of 29.5%.
The renowned biotechnology company has a market capitalization of $21.41 billion. ILMN’s earnings yield of 3.7% is well ahead of the industry’s -16.8% yield. In the trailing four quarters, it surpassed estimates on all occasions, delivering an average surprise of 12.2%.
Let’s delve deeper.
Tailwinds Behind ILMN StockClinical Demand Remains the Key Driver: Illumina continues to benefit from the broader adoption of NGS-based testing, with clinical markets now representing the majority of sequencing consumables revenues in first-quarter 2026. Management cited continued adoption of sequencing-based diagnostics and growing use of sequencing-intensive tests, including comprehensive genomic profiling and whole genome sequencing, as drivers of higher sequencing intensity. Clinical sequencing consumables demand grew 20%, excluding China, for the second consecutive quarter. Management continues to expect most clinical volumes to transition to NovaSeq X by the end of 2026.
Image Source: Zacks Investment Research
Sharpened Focus on Core Genomics: Following the spin-off of GRAIL in June 2024, Illumina has continued to center its strategy on the core sequencing franchise while scaling into adjacent multiomics and data offerings. The company is aiming for high-single-digit revenue growth by 2027, along with double-digits to teens annual earnings per share (EPS) growth.
First-quarter 2026 results reinforced that direction, with revenues, margins and non-GAAP EPS exceeding guidance. Growth was recorded across all regions, excluding China. Management also raised full-year 2026 guidance, now expecting revenues in the range of $4.52-$4.62 billion and non-GAAP diluted EPS in the range of $5.15-$5.30, alongside a modest step-up in the non-GAAP operating margin outlook between 23.4% and 23.6%.
NovaSeq X Placements and Transition Progress: Illumina’s core sequencing business remains anchored by NovaSeq X. First-quarter 2026 placements exceeded 80 units, around 20 more than the prior-year quarter and above the company’s targeted quarterly range. Demand remains strong for the platform, especially with clinical. Transition progress also continued, with approximately 82% of volumes and 55% of revenues transitioned to NovaSeq X in the first quarter, and roughly 90% of research and applied volume now on the platform. This positioning reduces prior transition-related friction and should allow a cleaner revenue response when research activity normalizes.
What Ails ILMN?Setbacks in the China Market: Illumina continues to face constrained demand in Greater China amid ongoing regulatory and geopolitical uncertainty, keeping the region out of step with the rest of the business. In first-quarter 2026, Greater China revenues were $52 million, down 27.8% year over year. Management highlighted growth across all regions, excluding China and continues to frame core trends on a rest-of-world basis. This dynamic reduces the company’s ability to benefit from installed-base expansion and instrument placements in a large end market that historically supported both system demand and consumables pull-through.
Macroeconomic Pressures Remain a Concern: Illumina continues to operate in a higher-cost environment shaped by tariffs and supply-chain inflation, which can affect both demand and margins. Despite the first-quarter 2026 non-GAAP gross margin being up 80 bps year over year, management noted tariffs were still a partial offset to underlying cost efficiencies and revenue leverage. The second-quarter guidance calls for an operating margin of around 22%, partly reflecting near-term inflationary impacts tied to freight and higher electronic component costs.
ILMN Stock Estimate TrendThe Zacks Consensus Estimate for ILMN’s 2026 EPS has increased 1.2% to $5.18 in the past 30 days.
The Zacks Consensus Estimate for the company’s 2026 revenues is pegged at $4.56 billion. This suggests a 5.1% rise from the year-ago reported number.
Key PicksSome better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Align Technology (ALGN - Free Report) and Phibro Animal Health (PAHC - Free Report) .
Globus Medical has an earnings yield of 6.1% compared to the industry’s negative 1.1% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 26.3%. GMED shares have rallied 29.7% against the industry’s 10.3% fall over the past year.
GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technology, carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 10.3% for fiscal 2026 compared with the industry’s 9.5% growth. Shares of the company have dropped 15% compared to the industry’s 1.8% growth. ALGN’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 7.8%.
Phibro Animal Health, carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.1%. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 16.3%. PAHC shares have rallied 45.8% against the industry’s 29.5% decline over the past year.
Former Labcorp Chairman and CEO brings deep healthcare, diagnostics, and clinical expertise to Illumina's Board
, /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today confirmed the election of David P. King to its Board of Directors, effective immediately following the company's annual meeting of shareholders. Mr. King's election marks an important addition to Illumina's Board as the company accelerates its clinical strategy to integrate genomics more broadly into the standard of care.
"We are delighted to welcome David to the Illumina Board," said Jacob Thaysen, chief executive officer of Illumina. "David brings deep regulatory knowledge, broad industry credibility, and the respect earned over decades at the forefront of healthcare and life sciences. Under his leadership at Labcorp, the company tripled in size through organic growth and strategic acquisitions. His perspective across diagnostics, healthcare delivery, and board governance will strengthen our ability to deliver long-term impact for patients, customers, and shareholders."
Mr. King is the former Executive Chairman and Chief Executive Officer of Labcorp. Under his leadership, Labcorp entered the Fortune 500, and was recognized by Fortune as one of the World's Most Admired Companies.
Mr. King joins the Board following the retirement of Frances Arnold, PhD, Robert S. Epstein, MD, and Gary S. Guthart, PhD, each of whom concluded distinguished tenures on the Board at the company's annual meeting.
About David P. King
David P. King was elected to Illumina's Board of Directors in 2026. Mr. King has extensive experience in the healthcare and life sciences sectors in executive and non-executive roles, including leading complex businesses at scale, driving operational excellence and commercial initiatives, and executing transformational change through M&A and organic growth.
Mr. King served as Chair and Chief Executive Officer as well as Executive Chairman of Laboratory Corporation of America Holdings (Labcorp) from 2007 to 2019. He provides strategic advisory services across the healthcare ecosystem through KingMan LLC. Mr. King also serves as Chair of Privia Health Group, Inc., as a director of Smith & Nephew, and has served in board leadership roles across a range of healthcare companies, including as Chair of ZimVie (2022–2025) and as Non-Executive Chair of PathGroup, LGC Limited, and AmSurg. Earlier in his career, Mr. King was a partner at Hogan & Hartson LLP (now Hogan Lovells) and served as an Assistant U.S. Attorney for the District of Maryland.
Mr. King received a B.A. from Princeton University and a J.D. from the University of Pennsylvania Law School.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Illumina (ILMN - Free Report) San Diego, CA.-based Illumina Inc. provides sequencing and array-based solutions for genetic and genomic analysis. The products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. Its customers include leading genomic research centers, academic institutions, government laboratories, hospitals as well as pharmaceutical, biotechnology, commercial molecular diagnostic and consumer genomics companies.
ILMN is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Additionally, the company could be a top pick for growth investors. ILMN has a Growth Style Score of B, forecasting year-over-year earnings growth of 7% for the current fiscal year.
Six analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.04 to $5.18 per share. ILMN also boasts an average earnings surprise of +12.2%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, ILMN should be on investors' short list.
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +23.7% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Illumina (ILMN - Free Report) San Diego, CA.-based Illumina Inc. provides sequencing and array-based solutions for genetic and genomic analysis. The products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. Its customers include leading genomic research centers, academic institutions, government laboratories, hospitals as well as pharmaceutical, biotechnology, commercial molecular diagnostic and consumer genomics companies.
ILMN is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
Momentum investors should take note of this Medical stock. ILMN has a Momentum Style Score of A, and shares are up 14.4% over the past four weeks.
Six analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.04 to $5.18 per share. ILMN boasts an average earnings surprise of +12.2%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, ILMN should be on investors' short list.
An advanced research workflow for fast, flexible detection of molecular residual disease during and following treatment
Solution is the first in a new WGS oncology portfolio, building on Illumina's history of leadership as foundation for MRD market
, /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced a new complete solution for molecular residual disease (MRD) research based on whole-genome sequencing (WGS). As a distributed kit, it will enable more labs to adopt MRD detection for clinical research. Now in early access for select clinical research partners, the MRD solution is the first whole-genome kit with flexibility to enable solid tumor MRD and blood cancer genomic profiling. It is the first in a new portfolio of WGS oncology research offerings, with additional solutions in development leveraging the latest advancements of the NovaSeq X™.
As a distributed WGS solution for MRD research, this technology will enable tumor fingerprinting and ctDNA tracking faster and for more patients. "In precision healthcare, early and accurate detection of molecular residual disease is critical to monitoring patients during and after cancer treatment," said Todd Christian, senior vice president of Services, Arrays and Genomic Access at Illumina. "Illumina's MRD solution for clinical research leverages the advanced sensitivity of whole-genome sequencing, coupled with unparalleled analysis, to enable our customers to more easily deliver the most precise information to advance MRD research. We aim to make WGS in oncology more accessible and scalable to support the integration of precision solutions into the standard of care."
The MRD solution supports "fingerprinting" through solid tumor samples, and MRD detection using blood samples, all compatible on NovaSeq Systems. The end-to-end research workflow can be completed in as fast as 5 days and is optimized for analytical sensitivity as low as 10 ppm, particularly important for early-stage and low-shedding tumors, including breast, ovarian, and renal.
Illumina's first-of-its-kind DRAGEN™ MRD analysis connects each fingerprint to serial circulating tumor DNA (ctDNA), offering customers flexible workflow combinations to meet their specific needs. Leveraging DRAGEN's unparalleled speed and accuracy, the new MRD solution has been optimized across thousands of samples to develop and demonstrate a ctDNA detection algorithm with 99.5% analytical specificity to distinguish true tumor signals from background noise.
Early adopters see strong performance with Illumina's WGS oncology solution
Several academic institutes evaluated the workflow. Mayo Clinic evaluated the solutioni on a small sample cohort and found high concordance among previously characterized paired samples. The results were also highly correlated with clinical and imaging results over time. The team is planning to expand the cohort for additional research with Mayo Clinic and other academic partners.
"We are looking forward to participating in early access and evidence generation for a tumor-informed, non-bespoke whole-genome sequencing approach to MRD," said Gang Zheng, MD, PhD and professor of Laboratory Medicine and Pathology at Mayo Clinic. "We have seen early pilot results across several solid tumor clinical samples that demonstrated the potential utility of highly sensitive solid tumor MRD detection, and we continue to pilot technologies that help us efficiently progress in our ability to analyze and translate complex genomic arrays."
Illumina and Bristol Myers Squibb will jointly present a poster at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on Sunday, May 31, from 9:00 a.m. to 12:00 p.m. (abstract ID 8591, poster board #381, Lung Cancer: Non–Small Cell Metastatic track). More information can be found at this link.
Roadmap to achieve ultra-sensitivity tailored for broader adoption
Built on recently announced NovaSeq X advancements, including 35B output and Q70 quality scores, a complementary research workflow that will deliver ultra-sensitive MRD detection in the single-digit ppm range leveraging duplex reads is currently in development.
"Illumina continues to push the NovaSeq X's capabilities to help our customers break barriers and unlock more discoveries," said Steve Barnard, PhD, chief technology officer of Illumina. "The new portfolio will bring advanced MRD research directly into labs with unmatched speed and sensitivity. The NovaSeq X is built for the long term, and Illumina will continue to deliver technologies that empower our customers to accelerate oncology breakthroughs."
Illumina technology also fuels centralized MRD providers leading the market today. The NovaSeq X offers foundational capabilities to support the quality, reliability, and scale needed as MRD adoption continues to grow. Illumina's new oncology portfolio builds upon the unique, integrated insight ecosystem of workflows, data and community across genomic, multiomic, and clinical research applications—anchored on the NovaSeq X.
Illumina's MRD research solution is available today for early access to select partners and will launch for global customers next year. Learn more here.
Use of forward-looking statements
This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) iiour ability to successfully implement NovaSeq X updates on a cost-effective and timely basis, (ii) challenges inherent in developing and launching new products and services, including modifying and scaling manufacturing operations, and reliance on third-party suppliers for critical components; (iii) our ability to manufacture robust instrumentation and consumables and develop reliable software solutions; and (iv) the acceptance and adoption by customers of our newly launched or updated products, which may or may not meet our expectations and theirs, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation and do not intend to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Automating library prep reduces hands-on time for customers using Pillar Biosciences oncoReveal® targeted oncology research panels
, /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and SPT Labtech today introduced the fireflyGO automation platform, a new benchtop liquid handling and library preparation solution that brings automation, speed, and simplicity to targeted oncology research. Integrated with the MiSeq™ i100 Series, fireflyGO helps laboratories streamline workflows, expand application flexibility, and unlock genomic insights with greater efficiency. By making next-generation sequencing (NGS) more accessible, scalable, and easier to adopt, Illumina continues to accelerate the shift toward genomics in cancer testing and as a standard of care in oncology.
Automating library prep reduces hands-on time for customers using Pillar Biosciences oncoReveal® targeted oncology research panels "Illumina is delivering end-to-end workflow solutions that help customers across the healthcare and research ecosystem make genomic testing more efficient and accessible," said Sandy Ottensmann, vice president and general manager of Global Clinical Solutions. "The fireflyGO platform paired with Illumina MiSeq i100 sequencers and Pillar Biosciences targeted panel assays advances research and serves as a catalyst for broadening genomic testing in cancer, driving shorter turnaround times leading to fast results."
Simplified automation for targeted oncology workflows
The fireflyGO platform automates library preparation and liquid handling as part of a streamlined workflow for sequencing and analysis on the MiSeq i100 Series. The workflow reduces manual touchpoints, providing higher reproducibility and reliability while reducing laboratory staffing needs. This solution also enables automation capabilities for a growing menu of NGS panels developed by Pillar Biosciences, supporting Illumina's targeted oncology research portfolio.
"Simplifying oncology workflows improves research and access to testing with the goal of delivering treatment faster. Our collaboration with Illumina reflects a shared focus on enabling efficient and accessible genomics workflows," said Rob Walton, chief executive officer at SPT Labtech. "By combining SPT Labtech's expertise in automation with Illumina's global strength in sequencing, we are positioned to help labs adopt genomics workflows."
Expanding Illumina's oncology research portfolio
Illumina is also expanding its Pillar Biosciences oncoReveal® targeted research portfolio with panels and workflows focused on solid tumor and hematologic malignancies and lymphoid conditions to enable rapid and simplified results:
The oncoReveal® Nexus 21 Gene Panel offers rapid solid tumor and hematological malignancy sequencing for multiple cancer types including NSCLC, endometrial, AML, B-Cell Lymphoma and MPN. The oncoReveal® Lymphoid Panel is an 84 gene DNA panel spanning high-value B-cell, T-cell, and lymphoblastic markers including full coverage of BTK to help genomically characterize lymphoid malignancies including CLL/SLL, WM/LPL, FL, MCL, DLBCL/LBCL, HCL, and multiple T-cell entities. These oncoReveal panels are currently available to customers worldwide.
Expanding access to NGS in oncology clinical research
The fireflyGO automation liquid handler, together with Illumina sequencing platforms and partner-developed content like Pillar oncoReveal panels, reinforces Illumina's mission to improve human health by unlocking the power of the genome.
To see and learn more about the fireflyGO platform with the MiSeq i100 and Pillar oncoReveal panels, visit the Illumina booth, #33106, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 29 through June 2.
Use of forward-looking statements
This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing, manufacturing, and launching new products and services; (ii) our and our partners' ability to deploy new products, services, and applications, and to expand the markets for genomics-related products and services; and (iii) the challenges associated with multiparty collaborations, including our reliance on the performance of such partners, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
